

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
13 May 2004 (13.05.2004)

PCT

(10) International Publication Number  
**WO 2004/039401 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 39/395**,  
C07K 16/18, G01N 33/574

(21) International Application Number:  
PCT/EP2003/012012

(22) International Filing Date: 29 October 2003 (29.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/422,009 29 October 2002 (29.10.2002) US

(71) Applicants and

(72) Inventors: **SALO**, Sirpa [FI/FI]; University of Oulu,  
Box 3000, FIN-90014 Oulu (FI). **TRYGGVASON**, Karl  
[SE/SE]; Dept. of Medical Biochemistry and Biophysics,  
Karolinska Institutet, S-171 77 Stockholm (SE).

(74) Agent: **VOSSIUS**, Volker; Geibelstrasse 6, 81679 Munich  
(DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished  
upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: USE OF ANTIBODIES TO THE GAMMA 2 CHAIN OF LALLMININ 5 TO INHIBIT TUMOR GROWTH AND METASTASIS

(57) Abstract: The present invention provides a methods and compositions for inhibiting tumor growth and/or metastasis involving the administering to a subject with a laminin 5-secreting tumor of an amount effective to inhibit tumor growth and/or metastasis of an antibody that binds to one or more epitopes of the laminin 5  $\gamma$ 2 chain.

WO 2004/039401 A2

## Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis

5

### CROSS REFERENCE

This application claims priority to U.S. Provisional Patent Application 60/422,009 filed October 29, 2002.

### 10 BACKGROUND OF THE INVENTION

Laminins are basement membrane glycoproteins with diverse biological functions including cell adhesion, proliferation, migration and differentiation. Thus far, 11 genetically distinct chains forming at least 12 laminin isoforms have been characterized. Every member of this growing protein family has a heterotrimeric chain composition of  $\alpha$ ,  $\beta$ , and  $\gamma$  chains that are  
15 formed through an intracellular self-assembly mechanism.

Laminin-5 is a specific component of epithelial basement membranes with the chain composition  $\alpha 3\beta 3\gamma 2$  (Kallunki, et al., J. Cell Biol. 119: 679-93, 1992). The  $\gamma 2$  chain has a mass of  $\approx 130$  kd and is thus smaller than the "classical"  $\approx 200$  kd  $\beta 1$  and  $\gamma 1$  light chains of laminin 1. Expression of laminin 5 chains is often up-regulated in epithelial cancers, such as squamous cell  
20 carcinomas and gastric carcinomas, but not in mesenchymally derived cancers (Larjava, et al., J. Clin. Invest. 92: 1425-35, 1993) (Pyke, et al., Am. J. Pathol. 145: 782-91, 1994) (Pyke, et al., Cancer Res. 55: 4132-9, 1995) (Tani, et al., Am. J. Pathol. 149: 781-93, 1996) (Orian-Rousseau, et al., J. Cell. Sci. 111: 19932004, 1998) (Sordat, et al., J. Pathol. 185: 44-52, 1998). However, down-regulation has been reported in epithelial prostate and breast carcinomas (Hao, J., Yang,  
25 Am. J. Pathol. 149: 1341-9, 1996) (Martin, et al., Mol. Med. 4: 602-613, 1998). In colon adenocarcinomas, both gene and protein expression of the  $\gamma 2$  chain seem to be a characteristic of cancer cells with a budding phenotype (Larjava, et al., J. Clin. Invest. 92: 1425-35, 1993) (Pyke, et al., Am. J. Pathol. 145: 782-91, 1994) (Pyke, et al., Cancer Res. 55: 4132-9, 1995). Tumor cell budding in colorectal carcinoma has also been associated with the presence of intracellular  
30 laminin-5 (Sordat, et al., J. Pathol. 185: 44-52, 1998).

The  $\gamma 2$  chain of laminin-5 has also been shown to be strongly expressed in malignant cells located at the invasion front of several human carcinomas, as determined by *in situ* hybridization and immunohistochemical staining (Pyke, C., Romer, J., Kallunki, P., Lund, L.R., Ralfkiaer, E., Dano, K. & Tryggvason, K. (1994) Am. J. Pathol. 145: 782-791; Pyke, C., Salo, S., Ralfkiaer, E., Romer, J., Dano, K. & Tryggvason, K. (1995) Cancer Res. 55: 4132-4139). However, no studies have shown that antibodies to the  $\gamma 2$  chain of laminin 5 can be used to inhibit tumor cell growth.

## SUMMARY OF THE INVENTION

The present invention provides antibodies, compositions and methods for inhibiting tumor growth and/or metastasis. In one aspect, the present invention provides antibodies that bind to one or more epitopes of domain III of the human laminin 5  $\gamma 2$  chain (SEQ ID NOS: 2 and 4).

In another aspect, the present invention provides a method for inhibiting tumor growth and/or metastasis comprising administering to a subject with a laminin 5-secreting tumor an amount effective to inhibit tumor growth and/or metastasis of an antibody that binds to one or more epitopes of the laminin 5  $\gamma 2$  chain. In one embodiment, the antibody binds to one or more epitopes of domain III of the laminin 5  $\gamma 2$  chain.

In a further aspect, the present invention provides a pharmaceutical composition comprising an antibody that binds to the laminin 5  $\gamma 2$  chain and one or more further anti-tumor agents. In various embodiments of this aspect, the antibody is selective for one or more epitopes in domain III of the laminin 5  $\gamma 2$  chain, and/or the further anti-tumor agent is a chemotherapeutic.

## BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 shows efficiency of human laminin-5 and recombinant human laminin  $\gamma 2$  chain for attachment of HaCat keratinocytes and KLN205 squamous carcinoma cells *in vitro*. The attachment efficiency was compared with the efficiency with which the cells bound to laminin-1. Substrate concentrations (10  $\mu\text{g/ml}$ ) providing maximum attachment to laminin-1 and laminin-5 were used. The results are presented as means  $\pm$  SD calculated from at least four duplicate series; the values for laminin-1 were given the arbitrary value of 100%.

FIGURES 2A-B show the effects of polyclonal  $\gamma 2$  chain antibodies on the migration of KLN205 squamous carcinoma cells in Boyden and Transwell chamber assays of migration.

FIGURE 3 shows tumor growth inhibition using Mab 5D5 and CPT-11 on day 31 in the HT29-e28 cell line.

5 FIGURES 4A-E show tumor growth curves for individual mice in the HT29-e28 study.

## DETAILED DESCRIPTION OF THE INVENTION

10 In one aspect, the present invention provides a method for inhibiting tumor growth and/or metastasis comprising administering to a subject with a laminin 5-secreting tumor an amount effective to inhibit tumor growth and/or metastasis of an antibody that binds to one or more epitopes of the laminin 5  $\gamma 2$  chain. In a preferred embodiment, the subject is a mammal; in a more preferred embodiment, the subject is human.

15 As used herein, the term "inhibiting tumor growth" means to reduce the amount of tumor growth that would occur in the absence of treatment, and includes decrease in tumor size and/or decrease in the rate of tumor growth.

As used herein, the term "inhibiting tumor metastasis" means to reduce the amount of tumor metastasis that would occur in the absence of treatment, and includes decrease in the number and/or size of metastases.

20 As used herein, the term "laminin-5 secreting tumor" means a tumor that expresses detectable amounts of laminin 5. Such tumors include, but are not limited to, carcinomas. Such carcinomas include, but are not limited to squamous cell carcinomas (including but not limited to squamous cell carcinoma of skin, cervix, and vulva), gastric carcinomas, colon adenocarcinomas, colorectal carcinomas, and cervical carcinomas.

25 As used herein, the term "laminin 5  $\gamma 2$  chain" preferably refers to the human laminin 5  $\gamma 2$  chain, with protein sequences comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, and derivatives thereof.

As used herein, the term "epitope" refers to a specific site within the protein that is bound by the antibody, which includes both linear and non-linear epitopes.

30 In a preferred embodiment, the antibody binds to one or more epitopes of domain III of the laminin 5  $\gamma 2$  chain. As used herein, the term "domain III of the laminin 5  $\gamma 2$  chain" refers to

a 177 amino acid region of SEQ ID NO:2 between residues 391 and 567 (Kallunki et al., J. Cell Biol. 119:679-693 (1992)), which is presented herein as SEQ ID NO:8. In a further preferred embodiment, the antibody binds to one or more epitopes within domain III that are contained within the amino acid sequence of SEQ ID NO:6 and does not bind to epitopes within domain III that are within the amino acid sequence of SEQ ID NOS: 9 and 10.

The antibody can be a polyclonal antibody or a monoclonal antibody, but preferably is a monoclonal antibody. For use in humans, humanized monoclonal antibodies are especially preferred.

In a further embodiment, the methods of the invention further comprises treating the subject with chemotherapy and/or radiation therapy, whereby the use of the antibody permits a reduction in the chemotherapy and/or radiation dosage necessary to inhibit tumor growth and/or metastasis. Any reduction in chemotherapeutic or radiation dosage benefits the patient by resulting in fewer and decreased side effects relative to standard chemotherapy and/or radiation therapy treatment.

In this embodiment, the antibody may be administered prior to, at the time of, or shortly after a given round of treatment with chemotherapeutic and/or radiation therapy. In a preferred embodiment, the antibody is administered prior to or simultaneously with a given round of chemotherapy and/or radiation therapy. In a most preferred embodiment, the antibody is administered prior to or simultaneously with each round of chemotherapy and/or radiation therapy. The exact timing of antibody administration will be determined by an attending physician based on a number of factors, but the antibody is generally administered between 24 hours before a given round of chemotherapy and/or radiation therapy and simultaneously with a given round of chemotherapy and/or radiation therapy.

The methods of the invention are appropriate for use with chemotherapy using one or more cytotoxic agent (ie: chemotherapeutic), including, but not limited to, cyclophosphamide, taxol, 5-fluorouracil, adriamycin, cisplatinum, methotrexate, cytosine arabinoside, mitomycin C, prednisone, vindesine, carbaplatinum, and vincristine. The cytotoxic agent can also be an antiviral compound which is capable of destroying proliferating cells. For a general discussion of cytotoxic agents used in chemotherapy, see Sathe, M. et al., Cancer Chemotherapeutic Agents: Handbook of Clinical Data (1978), hereby incorporated by reference.

The methods of the invention are also particularly suitable for those patients in need of repeated or high doses of chemotherapy and/or radiation therapy.

In practicing the invention, the amount or dosage range of antibody employed is one that effectively inhibits tumor growth and/or metastasis. The actual dosage range is based on a variety of factors, including the age, weight, sex, medical condition of the individual, the severity of the condition, and the route of administration. An inhibiting amount of antibody that can be employed ranges generally between 0.01 µg/kg body weight and 15 mg/kg body weight, preferably ranging between 0.05 µg/kg and 10 mg/kg body weight, more preferably between 1 µg /kg and 10 mg/kg body weight, and even more preferably between about 10 µg /kg and 5 mg/kg body weight.

The antibody may be administered by any suitable route, but is preferably administered parenterally in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. The term "parenteral" as used herein includes, subcutaneous, intravenous, intraarterial, intramuscular, intrasternal, intratendinous, intraspinal, intracranial, intrathoracic, infusion techniques or intraperitoneally. In preferred embodiments, antibody is administered intravenously or subcutaneously.

The antibody may be made up in a solid form (including granules, powders or suppositories) or in a liquid form (*e.g.*, solutions, suspensions, or emulsions). Antibody may be applied in a variety of solutions. Suitable solutions for use in accordance with the invention are sterile, dissolve sufficient amounts of the antibody, and are not harmful for the proposed application.

The antibody may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc.

For administration, the antibody is ordinarily combined with one or more adjuvants appropriate for the indicated route of administration. The compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanolic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration. Alternatively, the antibody may be dissolved in saline, water, polyethylene glycol, propylene glycol, carboxymethyl cellulose colloidal solutions, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, and/or various buffers.

Other adjuvants and modes of administration are well known in the pharmaceutical art. The carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials well known in the art.

In another aspect, the present invention provides isolated antibodies that bind to one or more epitopes of domain III of the laminin 5  $\gamma$ 2 chain, hybridoma cells that produce isolated monoclonal antibodies, and pharmaceutical compositions comprising such monoclonals. In a further preferred embodiment, the isolated antibody binds to one or more epitopes within the amino acid sequence of SEQ ID NO:6 and does not bind to epitopes within the amino acid sequence of SEQ ID NOS: 9 and 10. The isolated antibody can be a polyclonal antibody or a monoclonal antibody, but preferably is a monoclonal antibody. In a further embodiment, the isolated antibodies are humanized. In a further embodiment, the isolated antibody is prepared as a pharmaceutical composition, combined with one or more appropriate pharmaceutical carriers, as described above.

These isolated antibodies are useful in all of the methods of the invention, as well as in diagnostic use for detecting the presence of invasive cells in a tissue sample. In a preferred embodiment, diagnostic use of the isolated antibodies of the invention comprises contacting a tumor tissue with one or more isolated antibodies to form an immunocomplex, and detecting formation of the immunocomplex, wherein the formation of the immunocomplex correlates with the presence of invasive cells in the tissue. The contacting can be performed *in vivo*, using labeled isolated antibodies and standard imaging techniques, or can be performed *in vitro* on tissue samples.

In a preferred embodiment, the tissue is a tumor tissue. In a further preferred embodiment, the tumor tissue is a laminin 5 secreting tumor tissue. More preferably, the tumor tissue is a carcinoma, including but are not limited to squamous cell carcinomas (including but not limited to squamous cell carcinoma of skin, cervix, and vulva), gastric carcinomas, colon adenocarcinomas, colorectal carcinomas, and cervical carcinomas.

In a further preferred embodiment of this aspect of the invention, the isolated monoclonal antibodies are of the IgG isotype. In a further preferred embodiment, the isolated monoclonal antibodies are selected from the group consisting of those designated herein as 4G1, 5D5 and 6C12, and the hybridomas expressing these monoclonals, which are deposited with the American Type Tissue Collection as ATCC accession numbers ----, ----, and ----. A more detailed

description of the production of these particular hybridomas and monoclonal antibodies, and their use, is provided below.

The additional components of pharmaceutical compositions comprising one or more of these isolated antibodies are as described above.

5       Antibodies can be made by well-known methods, such as described in Harlow and Lane, Antibodies; A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., (1988). In one example, pre-immune serum is collected prior to the first immunization. A peptide portion of the amino acid sequence of a laminin 5  $\gamma$ 2 chain polypeptide, together with an appropriate adjuvant, is injected into an animal in an amount and at intervals sufficient to elicit  
10       an immune response. Animals are bled at regular intervals, preferably weekly, to determine antibody titer. The animals may or may not receive booster injections following the initial immunization. At about 7 days after each booster immunization, or about weekly after a single immunization, the animals are bled, the serum collected, and aliquots are stored at about -20° C. Polyclonal antibodies against the laminin 5  $\gamma$ 2 chain polypeptides can then be purified directly by  
15       passing serum collected from the animal through a column to which non-antigen-related proteins prepared from the same expression system without the laminin 5  $\gamma$ 2 chain polypeptides bound.

Monoclonal antibodies can be produced by obtaining spleen cells from the animal. (See Kohler and Milstein, Nature 256, 495-497 (1975)). In one example, monoclonal antibodies (mAb) of interest are prepared by immunizing inbred mice with a laminin 5  $\gamma$ 2 chain polypeptide,  
20       or portion thereof. The mice are immunized by the IP or SC route in an amount and at intervals sufficient to elicit an immune response. The mice receive an initial immunization on day 0 and are rested for about 3 to about 30 weeks. Immunized mice are given one or more booster immunizations of by the intravenous (IV) route. Lymphocytes from antibody positive mice are obtained by removing spleens from immunized mice by standard procedures known in the art.  
25       Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner under conditions that allow formation of stable hybridomas. The antibody producing cells and fusion partner cells are fused in polyethylene glycol at concentrations from about 30% to about 50%. Fused hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin supplemented Dulbecco's Modified Eagles Medium (DMEM) by procedures known  
30       in the art. Supernatant fluids are collected from growth positive wells and are screened for antibody production by an immunoassay such as solid phase immunoradioassay. Hybridoma



cells from antibody positive wells are cloned by a technique such as the soft agar technique of MacPherson, Soft Agar Techniques, in Tissue Culture Methods and Applications, Kruse and Paterson, Eds., Academic Press, 1973.

To generate such an antibody response, a laminin 5  $\gamma 2$  chain polypeptide or portion thereof is typically formulated with a pharmaceutically acceptable carrier for parenteral administration. Such acceptable adjuvants include, but are not limited to, Freund's complete, Freund's incomplete, alum-precipitate, water in oil emulsion containing *Corynebacterium parvum* and tRNA. The formulation of such compositions, including the concentration of the polypeptide and the selection of the vehicle and other components, is within the knowledge of those of skill of the art.

The term antibody as used herein is intended to include antibody fragments thereof which are selectively reactive with the laminin 5  $\gamma 2$  chain polypeptides. Antibodies can be fragmented using conventional techniques, and the fragments screened for utility in the same manner as described above for whole antibodies. For example,  $F(ab')_2$  fragments can be generated by treating antibody with pepsin. The resulting  $F(ab')_2$  fragment can be treated to reduce disulfide bridges to produce Fab' fragments.

In another aspect, the present invention provides pharmaceutical compositions comprising an antibody that binds to the laminin 5  $\gamma 2$  chain and one or more further anti-tumor agent. In a preferred embodiment of this aspect of the invention, the antibody binds to one or more epitopes in domain III of the laminin 5  $\gamma 2$  chain, as described above. In a further preferred embodiment, the isolated antibody binds to one or more epitopes within the amino acid sequence of SEQ ID NO:6 and does not bind to epitopes within the amino acid sequence of SEQ ID NOS: 9 and 10. The antibody can be a polyclonal antibody or a monoclonal antibody, but preferably is a monoclonal antibody. In a further preferred embodiment of this aspect of the invention, the further anti-tumor agent is a chemotherapeutic agent, such as one or more of those described above. The components of the pharmaceutical composition may be pre-mixed together or may be combined at any time prior to administration to a patient in need thereof.

The examples below are meant by way of illustration, and are not meant to be limiting as to the scope of the instant disclosure.

**EXAMPLE 1**

The following example demonstrates the effect of laminin-5, including the  $\gamma 2$  chain of laminin-5, on cell adhesion and cell migration.

**5    Materials and Methods*****Cells and Cell Culture***

A mouse squamous cell carcinoma cell line, KLN205 (cat. no. ATCC CRL-1453), was obtained from American Type Culture Collection (Rockville, MD). The cells were maintained as monolayer cultures in Eagle's minimum essential medium (MEM) containing non-essential  
10    amino acids and Earle's BSS supplemented with 10% fetal calf serum (FCS). The HaCat human keratinocyte cell line was a kind gift from Dr. Fuzenig (Heidelberg, Germany). The HaCat cells were cultured in Dulbecco's MEM supplemented with 10% FCS. However, when the cells were cultured for the production of laminin-5, the medium was replaced by serum-free medium.

**15    *Preparation of Proteins***

Mouse EHS laminin (laminin-1) was obtained from GIBCO BRL. Fibronectin was purified from FCS using a gelatin-Sepharose 4B column (Sigma) as described in Vuento, M. & Vaheri, A. (1979) Biochem. J. 183: 331-337.34 and Gillies, R. J., Didier, N. & Denton, M. (1986) Anal. Biochem. 159: 109-113. Human laminin-5 was immunoaffinity purified from the  
20    media of HaCat cells cultured for three days in the absence of serum. Briefly, the medium was first passed through a 5 ml gelatin-Sepharose column (Sigma, St. Louis, MO) to ensure the complete absence of fibronectin from the protein preparation, after which the medium was passed through a 10 ml anti-laminin  $\gamma 2$ -Sepharose affinity column in order to bind laminin-5 molecules. Both columns were equilibrated in phosphate-buffered saline. The anti-laminin  $\gamma 2$ -  
25    Sepharose affinity column was prepared by coupling a Protein A-purified anti- $\gamma 2$  IgG (8 mg/ml) to 10 ml of CNBr-activated Sepharose (Pharmacia, Uppsala, Sweden). The anti- $\gamma 2$  IgG was purified from a rabbit polyclonal antiserum prepared against a GST-fusion protein containing domain III of the  $\gamma 2$  chain (Pyke, C., Salo, S., Ralfkiaer, E., Romer, J., Dano, K. & Tryggvason, K. (1995) Cancer Res. 55: 4132-4139). The laminin-5 was eluted from the immunoaffinity  
30    column using 50 mM triethanolamine, pH 11.25, 0.1% Triton X-100 and neutralized directly

with 1 M Tris-HCl, pH 7.0. Collected fractions were analyzed by SDS-PAGE and Western blotting using the same polyclonal antibodies as used for the preparation of the affinity column. Fractions containing laminin-5 were pooled and dialyzed against 50 mM Tris-HCl, 0,1 M NaCl, pH 7.4. Some batches of laminin-5 were denatured with 5 M urea and renatured to study the effects of the treatment on adhesion and migration properties.

#### *Generation of Recombinant Baculovirus and Expression of Recombinant Laminin 2 Chain*

The  $\gamma 2$  chain of laminin-5 was expressed as recombinant protein using the baculovirus system and purified for studies on its functional properties. A full-length human laminin  $\gamma 2$  chain cDNA containing 6 bp of the 5' UTR and 822 bp of the 3' UTR was constructed from four overlapping cDNA clones L52, HT2-7, L15 and L61 (Kallunki, P., Sainio, K., Eddy, R., Byers, M., Kallunki, T., Sariola, H., Beck, K., Hirvonen, H., Shows, T.B. & Tryggvason, K. (1992) J. Cell Biol. 119: 679-693). The resulting 4,402 bp cDNA was analyzed by restriction enzyme mapping and partial sequencing, and cloned into the pVL1393 recombinant transfer plasmid prior to transfer into the AcNPV- $\gamma 2$  baculovirus vector kindly provided by Max Summers (Texas A&M University). This baculovirus vector containing the human laminin  $\gamma 2$  chain cDNA under the transcriptional control of the polyhedrin promoter was produced and purified following standard procedures, except that it was first enriched according to the method of Pen, et al. (Pen, J., Welling, G.W. & Welling-Wester, S. (1989), Nucl. Acid. Res. 17: 451) from the virus containing medium obtained by co-transfecting Sf9 cells with the wild-type virus (AcNPV) DNA and the recombinant transfer vector pVL 1393- $\gamma 2$ . For expression of the recombinant protein, High Five (H5) cells were infected with the recombinant virus at a multiplicity of infection (MOI) of 5-10 pfu per cell by using standard protocols.

The recombinant  $\gamma 2$  chain was purified by first resuspending the cells in 10 volumes of 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 2.5 mM EDTA, 1% Triton X-100, 1 mM PMSF and 1 mM NEM followed by homogenization in a Dounce homogenizer. The protein was extracted for 60 minutes on ice and solubilized proteins were removed by centrifugation at 1500 x g for 10 minutes at 4° C. The pellet was extracted again with buffer containing 1-3 M urea. The recombinant  $\gamma 2$  chain was extracted with a buffer containing 5 M urea, and renatured by dialysis against 50 mM Tris-HCl, pH 7.4, 100 mM NaCl.

### *Preparation of Antibodies*

Polyclonal antiserum against domain III of the laminin  $\gamma 2$  chain was prepared and characterized as described previously. Briefly, rabbits were immunized s.c. four times using a  $\gamma 2$ -GST fusion protein as antigen. The antigen contained 177 amino acid residues (res. # 391-567) from domain III of the  $\gamma 2$  (SEQ ID NO:8) (Kallunki, P., Sainio, K., Eddy, R., Byers, M., Kallunki, T., Sariola, H., Beck, K., Hirvonen, H., Shows, T.B. & Tryggvason, K. (1992) J. Cell Biol. 119: 679-693). Antibodies against the GST-epitopes were removed from the antisera by negative immunoadsorption with GST-Sepharose made by coupling *E. coli* expressed GST protein to CNBr-activated Sepharore. The removal of anti-GST IgG was ensured by Western blotting analysis with GST-specific antibodies. The specificity of the antibody against the laminin  $\gamma 2$  chain was also tested by Western blotting as well as by ELISA.

Polyclonal antibody against the C-terminus of the laminin  $\gamma 2$  chain was produced in rabbits essentially as above for domain III using a  $\gamma 2$ -GST fusion protein as antigen. The antigen contained 161 amino acids (res. # 1017-1178) from domain I/II of the  $\gamma 2$  chain and antibodies against the GST-epitopes were removed from the antisera by negative immunoadsorption with GST-Sepharose. The specificity of the antibody was tested by Western blotting and ELISA.

Polyclonal antiserum against laminin-1 was a kind gift of Dr. Foidart (University of Liege, Belgium). Normal rabbit serum was obtained prior to immunization from the rabbits used for immunization. IgG from the laminin-1 and laminin  $\gamma 2$  chain antisera, as well as from normal rabbit serum, was purified using Protein A Sepharose (Pharmacia, Uppsala, Sweden).

### *Cell Adhesion Assay*

Microtiter plates (96 wells: Nunc, Copenhagen, Denmark) were coated with 100  $\mu$ l/well of laminin-1 (10  $\mu$ g/ml), laminin-5 (10  $\mu$ g/ml), or recombinant laminin  $\gamma 2$  chain (10  $\mu$ g/ml) in PBS or 50 mM Tris-HCl, pH 7.4 by incubating the plates overnight at 4° C. Control wells were uncoated or coated with the same amounts of BSA. In some experiment the proteins were first denatured by dialysis overnight against 5 M urea, 50 mM Tris-HCl, pH 7.5 and then renatured by dialysis against 50 mM Tris-HCl, pH 7.5. Potential remaining active sites on the plates were blocked with 150  $\mu$ l of 10 mg/ml BSA in PBS for 2 hours at room temperature. The wells were

washed with PBS, and 100 ml of Eagle's MEM containing 5 mg/ml BSA was added. For the adhesion assays, KLN205 cells were detached from subconfluent cell culture dishes with trypsin-EDTA (0.25%-0.03%) and resuspended in Eagle's MEM/BSA (5 mg/ml) at a concentration of  $2 \times 10^5$  cells/ml and allowed to recover for 20 minutes at 37° C. A total of 20,000 cells were then added to each well and allowed to attach for an additional 90 minutes at 37° C. The extent of cell adhesion was determined by measuring color yields at 600 nm, following fixation with 3% paraformaldehyde and staining with 0.1% crystal violet. For inhibition assays with the anti- $\gamma 2$  antibody, the substrate coated wells were incubated with 20  $\mu$ g/ml of anti- $\gamma 2$  chain IgG in PBS for 60 minutes prior to incubations with the cells.

#### *Migration Assay*

The effect of endogenous laminin-5 on migration of KLN205 cells was determined by using a modified Boyden chamber assay, as described by Hujanen and Terranova (Hujanen, E. & Terranova, V.P. (1985) Cancer Res. 45: 3517-3521), and the effect of exogenous laminin-5 by using a modified Transwell assay, as described by Pelletier, et al. (Pelletier, A.J., Kunicki, T. and Quaranta, V. (1996), J. Biol. Chem. 271:364).

The Boyden chamber assay was carried out as follows. Polycarbonate filters (pore size 10  $\mu$ m, diameter 12 mm; Costar, Cambridge, MA) were coated with 2.5  $\mu$ g of EHS type IV collagen, and used to separate the upper and lower compartments of the 50  $\mu$ l chamber. A total of  $1 \times 10^5$  cells in Eagle's MEM containing 0.1% BSA were placed in the upper compartment, and the lower compartment was filled with medium with or without chemoattractants (50  $\mu$ g/ml laminin-1 or fibronectin). To study the effect of the laminin  $\gamma 2$  chain antibodies on cell migration, anti- $\gamma 2$  (III) IgG or anti- $\gamma 2$  (C-term) IgG was added to the upper compartment together with the cells at a concentration of 20  $\mu$ g/ml. Normal rabbit IgG was used as a negative control. After an 8-hour incubation at 37° C in a humidified atmosphere, the filters were removed, fixed and stained (Diff-Quick, Baxter Diagnostics, Tübingen, Germany). The cells that had not migrated were removed from the upper surface of the filter with cotton swabs. Migration of cells was quantified by counting the cells on the lower surface of each filter in 10 randomly selected high power fields (x400). All assays were performed in triplicate.

The "Transwell" plate assay (Transwell plates with pore size 12  $\mu\text{m}$ , diameter 12 mm; Costar, Cambridge, MA) was used to determine the effect of exogenous laminin-5 on cell migration. The lower side of the membrane was coated with 2.5  $\mu\text{g}$  of EHS type IV collagen for 3 hours at room temperature. Both sides were blocked with 1% bovine serum albumin for 1 hour. A total of  $1 \times 10^5$  cells were added per well in the upper compartment in Eagle's MEM containing 10% FCS, and the lower compartment was filled with 2.5  $\mu\text{g}/\text{ml}$  laminin-5 as a chemoattractant. Antibodies against the C-terminus and domain III of the  $\gamma 2$  chains or nonimmune IgG were added to the upper compartment, together with the cells at a concentration 20  $\mu\text{g}/\text{ml}$ . Following a 16-hour incubation at 37° C the cells were fixed and stained. Cells on the top surface of the membrane were removed with cotton swabs, and cells that had migrated to the lower side of the membrane were counted (12 fields  $\pm$  S.D.).

#### *Immunohistochemical Staining*

Five  $\mu\text{m}$  thick paraffin sections were stained with polyclonal antibodies against laminin-1 or the  $\gamma 2$  chain of laminin-5. In brief, the paraffin sections were first incubated with 0.4% pepsin in 0.1 M HCl at 37° C for 20 minutes to expose the antigens, blocked for nonspecific binding with 5% newborn rabbit serum, 0.1% BSA, and then incubated for 1 hour at 37° C with the polyclonal IgG diluted in TBS to 5-10  $\mu\text{g}/\text{ml}$ . Subsequently, a biotinylated swine-anti-rabbit antibody was applied, followed by incubation with a 1:400 dilution of Horseradish-Peroxidase-Avidin-Biotin-Complex (DAKO, Copenhagen, Denmark). The color was developed in diaminobentsamidine (DAB), followed by counterstaining of the slides with hematoxylin.

#### *Results*

##### *Characterization of Proteins and Epithelium-Derived Cells*

Immunopurified trimeric laminin-5, isolated from the culture medium of HaCat cells contained two major bands when analyzed by SDS-PAGE. These bands corresponded, respectively, to the 165 kDa  $\gamma 2$  chain, and the 155 kDa and 140 kDa  $\gamma 2$  and  $\beta 3$  chains migrating as a single band, as reported previously. Additionally, a weak band of about 105 kDa corresponding to the processed  $\gamma 2$  chain could be observed.

Full-length human recombinant laminin  $\gamma 2$  chain was produced in High-5 *Spodoptera frugiperda* insect cells using the baculovirus system. Since the  $\gamma 2$  chain was not secreted to the culture medium, possibly because it was not assembled intracellularly into a normal heterotrimer, it was isolated from the cell fraction as described in *Materials and Methods*. The protein was  
5 extracted under denaturing conditions using 5 M urea, renatured by extensive dialysis against 50 mM Tris-HCl, 100 mM NaCl, pH 7.4, and purified. The purified recombinant  $\gamma 2$  chain was full length (approximately 155 kDa) and highly pure as determined by SDS-PAGE analysis.

The HaCat human keratinocytes and mouse KLN205 squamous carcinoma cells were shown to express laminin-5, based on Northern blot analyses and immunostaining, using a  
10 cDNA probe and/or polyclonal antibodies specific for the  $\gamma 2$  chain, respectively. Furthermore, the KLN205 cells developed  $\gamma 2$  chain positive primary tumors and metastases in mice *in vivo* (data not shown). Following intramuscular or subcutaneous inoculations, large primary tumors developed in 4 weeks with numerous lung metastases after 4-6 weeks. KLN205 cells injected into the tail vein produced multiple lung tumors (experimental metastases) in four weeks.  
15 Consequently, both cell types were considered appropriate for the cell attachment and migration experiments carried out in this study.

#### *Laminin-5 Molecule, but not Recombinant Laminin $\gamma 2$ Chain, Promotes Cell Adhesion*

The laminin-5 and recombinant  $\gamma 2$  chain prepared in this study, as well as commercial  
20 laminin-1, were used as substrata in attachment assays (FIGURE 1) with the two epithelium-derived HaCat and KLN205 cell lines that both express laminin-5. Both cell lines attached about 2.5 times more readily to laminin-1 than to plastic. Adhesion of the cells to laminin-5 appeared to be slightly higher than that to laminin-1, but the differences were not statistically significant. The cells attached equally well to laminin-5 preparations denatured in 5 M urea and then  
25 renatured by dialysis against 50 mM Tris-HCl, 100 mM NaCl, pH 7.4, as described for the recombinant  $\gamma 2$  chain above, indicating that this treatment did not affect the binding properties of the trimeric molecule. The attachment to laminin-5 did not significantly decrease in the presence of two different polyclonal antibodies made against the short or long arms of the  $\gamma 2$  chain or pre-IgG. Different amounts of the antibody against the short arm of the  $\gamma 2$  chain were also tested (up  
30 to 50  $\mu\text{g/ml}$ ), but no effects on cell adhesion were observed. When the cells were plated on the

recombinant  $\gamma 2$  chain alone, the attachment was not significantly higher than that to plastic, this attachment not being influenced by polyclonal antibodies against the  $\gamma 2$  chain. The data confirm previous results showing that trimeric laminin-5 promotes adhesion of epithelial cells, but the present results further strongly suggest that this adhesion is not mediated by the  $\gamma 2$  chain.

5

*Antibodies Against Laminin  $\gamma 2$  Domain III, But Not Domain I/II, Inhibit Cell Migration*

The potential role of the  $\gamma 2$  chain of laminin-5 in cell migration was examined for the KLN205 cells *in vitro* using Boyden and Transwell chamber assays as described in *Materials and Methods*.

10 Migration was first studied in the Boyden chamber assay using laminin-1 and fibronectin in the lower chamber as chemoattractants (See **Figure 2A**). The two compartments of the chemotactic Boyden chambers were separated by a type IV collagen coated porous filter (pore size 8  $\mu\text{m}$ ). The cells ( $1 \times 10^5$ ) in MEM containing 0.1% BSA were placed in the upper compartment, and laminin-1 (+/-) or fibronectin (-/+) in MEM containing 0.1% BSA were added as chemoattractants to the lower compartment. IgG against  $\gamma 2$  chain domains III, I/II or preimmune IgG was added to the upper compartment with the cells at a concentration of 20  $\mu\text{g/ml}$ . After an 8-hour incubation at 37°C the filters were removed and migration of cells to the lower surface of the filter was quantitated. The data are expressed as percentage of migrated cells (+/- SD (bars)) per high power field, setting migration in the presence of pre-immune IgG as 100%. Cells were counted in ten randomly selected high power fields to triplicate assays. When polyclonal IgG against the short arm of the  $\gamma 2$  chain was added to the upper compartment containing the cells, the migration of cells through the filter was decreased to about 35 to 45% of that observed with the preimmune serum. In contrast, the polyclonal IgG against C-terminal domain I/II did not affect migration of the cells.

25 The effects of the two antibodies were similarly used in the Transwell assay using native laminin-5 as chemoattractant in the lower compartment (See **Figure 2B**). The lower side of the membrane was coated with EHS type IV collagen, and the lower compartment was filled with 2.5  $\mu\text{g/ml}$  laminin-5 as a chemoattractant. Pre-immune IgG, IgG against the  $\gamma 2$  chain domains III or I/II were added to the upper chamber containing the cells. Following a 16-hour incubation the cells were fixed and cells at the lower side of the membrane were counted (12 fields +/- SD).



The results were essentially the same as in the Boyden chamber assay. Thus, addition of IgG raised against domain III of the  $\gamma 2$  chain inhibited the migration to about 50% as compared with preimmune IgG, while the polyclonal IgG against domain I/II did not affect the cell migration.

These *in vitro* results demonstrate that laminin-5 have a role in the locomotion of epithelium-derived cells, and that this function can be inhibited by antibodies directed against domain III of the  $\gamma 2$  chain.

Thus, antibodies against the short arm of the laminin  $\lambda 2$  chain inhibited the migration of KLN205 squamous carcinoma cells by about 55-65% as determined in the Boyden chamber migration assay. Interestingly, the antibodies used here were directed against 177 amino acid residues of domain III (SEQ ID NO:8) that when deleted by mutation cause lethal junctional epidermolysis bullosa. Accordingly, the short arm of the laminin  $\lambda 2$  chain is important for the interaction of this laminin isoform to other extracellular matrix proteins and this interaction is also involved in the cell migration process.

## EXAMPLE 2

The following example describes, in detail, the preparation of monoclonal antibodies according to the invention as well as demonstrating their use in inhibiting tumor cell growth in laminin-5 secreting tumors.

Monoclonal antibodies against the  $\gamma 2$  chain of laminin-5 were produced by immunizing Balb/c mice with 100 ug GST-laminin- $\gamma 2$ -III fusion protein as antigen. The GST-laminin-  $\gamma 2$ -III fusion protein contains human laminin-  $\gamma 2$ -chain amino acid residues 391-567 (SEQ ID NO:8). Subsequent to immunization, spleen cells from the immunized mice were fused with mouse myeloma cell obtained from cell line P3X63Ag.8.653 (ATCC #CRL-1580). The hybridoma clones were then screened in immunohistology on frozen and paraffin sections (human cervix carcinoma, normal cervix and normal skin) for the production of the anti-laminin-  $\gamma 2$  antibody. The staining result was compared to negative control, mouse normal serum and IgG, and to the positive result obtained with well-characterized anti-laminin-5,  $\gamma 2$  chain polyclonal antibody (described in Pyke, et al., 1995). The hybridoma clones were also screened in ELISA. The best hybridoma clones were picked and cloned again twice (single cell cloning) to ensure that the produced hybridoma cell line was monoclonal.

The following describes the details of the production of three specific hybridoma clones

and corresponding monoclonal antibodies produced therefrom. Characterization studies were conducted with respect to the 4G1, 5D5 and 6C12 monoclonal antibodies. Western blot analysis and ELISAs were carried out to confirm the specificity of the antibodies to the  $\gamma 2$  chain of laminin 5. Western blot analysis involved running recombinant laminin 5  $\gamma 2$  chain (as well as appropriate controls) in an SDS-PAGE gel, blotting the gel on a nylon membrane, and incubating the membrane with the antibodies

For ELISA, plates were coated with 100  $\mu$ l GST- $\gamma 2$ -III fusion protein (antigen) (Salo et al., Matrix Biology 18:197-210 (1999) at a concentration of 2.5  $\mu$ g/ml in 0.1M carbonate/bicarbonate buffer (pH 9) overnight at 4° C (0.25 $\mu$ g/well). The ELISA plate was then washed three times with a PBST solution (200  $\mu$ l) (10mM potassium phosphate, 150 mM NaCl), pH 7.5, and 0.05% Tween-20. Non-specific binding was then blocked by addition of BSA-PBS (1% bovine serum in PBS buffer (10mM K<sub>3</sub>P0<sub>4</sub>, 150 mM NaCl, pH 7.5)) (200 m/well) for a period of 90 minutes. To this, a dilution of negative controls (normal mouse serum) and a sample diluted in BSA-PBS (Mab 4G1, 5D5 or 6C12) were added and then the ELISA plate was incubated for 1 hour at room temperature. After incubation, the ELISA plate was then washed with PBST three times. Next, HRP-conjugated anti-mouse IgG secondary antibody (Peroxidase (HRP) conjugated Rabbit Anti-Mouse IgG (H+L), Jackson Laboratories #315-035-045) was added and the plate was incubated at room temperature for 30 minutes. The ELISA plate was then washed again three times with PBST solution (200 ml). An ABTS-peroxide substrate was then added to the wells (ABTS diluted in 0.1 M Na-citrate, pH5; diluted immediately before assay use 1ml to 10ml with Na citrate buffer + 2  $\mu$ l 30% hydrogen peroxide) and then the plate was allowed to incubate in the dark for 30 minutes. The absorbance was then read with a micro plate reader at 405 nm at 30 and 60 minutes.

These analyses demonstrated the specificity of the monoclonal antibodies for domain III of the laminin 5  $\gamma 2$  chain. Epitope mapping of the epitopes recognized by Mab 4G1, 5D5 or 6C12 indicated that they each bound epitopes within the amino acid sequence of SEQ ID NO:6 (which is a portion of domain III of the  $\gamma 2$  chain that lacks part of the amino and carboxy terminal portions of domain III), and did not bind to epitopes within the amino acid sequence of SEQ ID NOS: 9 and 10 (the 9 amino terminal and 41 carboxy terminal amino acids of domain III, respectively).

Monoclonal antibodies against the  $\gamma 2$  chain of laminin-5 were then tested for efficacy in inhibiting tumor cell growth in laminin-5 secreting tumors.

*Study 1: Tumor Growth in Immunosuppressed Mice*

The following study demonstrates the ability of IgG immunoglobulin against human laminin-5,  $\gamma 2$ -III-domain (Mab 5D5) to affect the number and size of metastases in immune deficient mice.

$10^6$  human squamous epithelial carcinoma cells were injected into the tail vein of immunosuppressed mice for tumor implantation. The cell lines used were human squamous epithelial carcinoma cells, cell line A431 and HSC-3. The cells were provided in suspensions in a medium containing DMEM-glutamax, 1% penicillin-streptomycin, 1% Na-pyruvate, 5% FCS. The cells were re-suspended in sterile Ca and Mg free PBS for inoculation. A control cell count was performed for the cell suspension at arrival and the cell density and the injected volume was recorded. The origin of the cells is HSC-3: Japan Health Science Research Resources Bank, JCRB 0623 A431: ATCC catalog number CRL-1555. The immunosuppressed mice were selected as they are susceptible to grow cells of human origin as is well known in the field. The tumor cells in groups 3 and 6 were injected into mice with test item (test item was 50  $\mu$ g/ml) for tumor implantation. The tumor cells were allowed to grow for one week after which the animal received intravenous injections of the test item twice a week for four weeks.

Table 1. Study Layout

Group	Mouse Strain		Animal Number	Cell Line	Treatment
1	Balb/c~nudet	5	1-5	-	-control, no treatment
2	Balb/c-nude <sup>1</sup>	5	6-10	HSC-3	+control, no treatment
3	Balb/c-nude <sup>1</sup>	5	11-15	HSC-3	Test item treatment: 50 $\mu$ g 5D5/mouse injection
4	SCID <sup>2</sup>	5	21-25	-	-control, no treatment
5	SCID~	5	26-30	A431	+control, no test item
6	SCIDZ	5	31-35	A431	Test item treatment: 50 $\mu$ g 5D5/mouse injection

<sup>1</sup> Balb/c-nude (BALBicABom-nu, M&B A/S, Denmark)

<sup>2</sup> Fox Chase Scid (C.B-17/lcr scid/scid, M&B A/S, Denmark) immunodeficient mice.

After the treatment period, the animals were killed and tissue samples were collected. Number and size of the tumors in different tissues were counted and compared.

#### 5 *Test Items and Dosing Solutions*

The test item was IgG immunoglobulin against human laminin-5,  $\gamma$ 2-III-domain (Mab 5D5). The test item was produced with monoclonal hybridoma method *in vitro* as set forth above. The test item (Mab 5D5) was suspended in sterile phosphate buffered saline (PBS) with a concentration of 1 mg/ml. The vehicle was sterilized using a 0.2  $\mu$ m filter. The delivered test  
10 item was diluted with sterile PBS 50:50 to give a dosing concentration of 500  $\mu$ g/ml.

The test item was administered intravenously into the lateral tail vein of the immunosuppressed mice in a volume of 0.1 ml/animal. The dosing was twice a week on Mondays and Thursdays. The first dose of test item was administered one week after the induction of experimental metastasis.

15 After four weeks of treatment (eight doses of test item), the animals were killed by exsanguination with cardiac puncture in CO<sub>2</sub> anesthesia. Blood was collected and serum separated and frozen in -20° C. A gross necropsy was performed and the macroscopic signs were recorded with special attention to macroscopic tumor masses, which were calculated and measured if possible. The following organs/tissues were collected and weighed: lungs, lymph  
20 nodes (cervical and mesenteric), liver, and spleen. The organs/tissues were rinsed in PBS and fixed in 4% phosphate buffered formalin.

#### *Clinical Signs*

Animal number 6 had a thickening of the tail from day 5 through the whole study. The  
25 tail of animal number 11 turned dark/black after tumor cell inoculation and eventually turned necrotic. Half of the tail was missing from day 7 onward. No other treatment related clinical signs were recorded. One animal (number 8, group 2) was found dead on the morning of the day following tumor cell inoculation. Gross necropsy did not reveal any macroscopic changes. All other animals survived in good condition during the whole study.

30

#### *Necropsy*

The injected tumor cells induced tumor growth almost only in the lungs. Other tissues with macroscopic metastases include spleen, liver, small intestine, and preputial gland. The SCID mice had changes in the liver which might be of microbial origin. In the lungs, the metastases were so numerous and so small that it was impractical to calculate or measure individual metastases.

The following Table 2 represents a summarization of the results of the mice treated from Table 1.

Table 2. Experimental Metastases in Lung

Group	Mouse Strain	N	Cell Line	Treatment	Number of Mice with Macroscopic Lung Metastases Observed
1	Balb/c-nude	5	-	-control, no treatment	-
2*	Balb/c-nude	5	HSC-3	+ control, no treatment	4/4 (full of mastastases)
3	Balb/c-nude	5	HSC-3	Test item treatment	1/5
4	SCID ~	5	-	-control, no treatment	-
5	SCID	5	A431	+control, no test item	3/5
6	SCID	5'	A431	Test item treatment	4/5

\* one mouse was dead at the end of the second study

As can be seen from Table 2 above, the treated Balb/c-nude mice had 1 of 5 mice with macroscopic lung metastases while 4 of 4 untreated control Balb/c-nude mice had macroscopic lung metastases.

### EXAMPLE 3

Monoclonal antibody 5D5 was tested against HT29 carcinomas in a tumor growth inhibition assay. The assay compared immunotherapy with 75 and 25  $\mu$ g/mouse 5D5, qod x 15, to conventional chemotherapy with 100 mg/kg CPT-11 (irinotecan/Campostar), qwk x 3.

#### *Methods and Materials*

Female nude athymic mice (Harlan) were 13 weeks of age on day 1 of the study. The

animals were fed *ad libitum* water (reverse osmosis, 1 ppm Cl) and the NIH 31 Modified and Irradiated Lab Diet® consisting of 18.0% protein, 5.0% fat, and 5.0% fiber. Mice were housed in static microisolators on a 12-hour light cycle at 21-22 ° C (70-72 ° F) and 40%-60% humidity.

## 5 Tumor Implantation

An HT29 carcinoma fragment (1 mm<sup>3</sup>) was implanted subcutaneously in the flank region of each mouse. When the tumors reached a size ranging from 62.5-126 mg, the mice were sorted into five treatment groups to provide a group mean tumor weights of 84.2-85.5 mg. Estimated tumor weight was calculated using the formula:

$$\text{Tumor Weight (mg)} = \frac{w^2 \times l}{2}$$

Where  $w$  = width and  $l$  = length in mm of the HT29 carcinoma.

Dosing solutions of 5D5 and control IgG were prepared fresh daily by dilution with phosphate-buffered saline. CPT-11 (Pharmacia; 20 mg/mL) was diluted with saline on each day of dosing.

On day 1, mice were sorted into five groups of animals ( $n = 10/\text{group}$ ), and dosing was initiated according to the protocols listed in Table 3.

Table 3. Protocol Design for the HT29-e29 Study

Group	n	Treatment Regimen I			
		Agent	mg/kg	Route	Schedule
1	10	No treatment.	n/a		
2	10	CPT-11	100	IP	Qwkx3
3	10	Control IgG	75 ug/ mouse	IV	Qod x 15
4	10	5D5	75 ug/ mouse	IV	Qod x 15
5	10	5D5	25 ug/ mouse	IV	Qod x 15~

As a positive reference drug, CPT- 11 was administered once per week for three weeks (qwk x 3) in 100 mg/kg doses. CPT- 11 was delivered i.p. in volumes of 0.2 ml/20 g body weight, which were body-weight adjusted. Doses of 5D5 or control mouse IgG were delivered intravenously in volumes of 0.2 mL/mouse. The antibody doses were not body-weight adjusted.

- 5 Untreated Group I mice served as controls for the CPT-11 therapy. Group 3 mice received 15 µg/mouse doses of control IgG once daily on alternate days (qod x 15). Mice in groups 4 and 5 received 75 and 25 ug/mouse doses of 5D5 x 15, respectively.

### Endpoint

- 10 Efficacy was evaluated in a tumor growth inhibition assay. Tumors were measured twice weekly until the study was terminated on day 31. Each animal was then euthanized and its HT29 carcinoma was excised and weighed. Treatment may produce complete tumor regression (CR) or partial tumor regression (PR) in an animal. In a CR response, there is no measurable tumor mass at the completion of the study. In a PR response, the tumor weight is lower than the weight  
15 on day, but greater than 0 mg. All tumors that did not regress were included in the calculation of tumor growth inhibition.

- The increase in tumor weight for each animal was calculated as the difference between the actual tumor weight at the end of the study and the calculated tumor weight on day 1. These values were used to calculate the group mean tumor weight increases. Tumor growth inhibition  
20 was calculated from the group mean tumor weight increases of treated and control mice by the following equation:

$$\%TGI = \left[ 1 - \left( \frac{\text{MeanNetTum or Weight}_{\text{Treated}}}{\text{MeanNet Tum or Weight}_{\text{control}}} \right) \right] \times 100 \%$$

25

### Toxicity

- The mice were weighed twice weekly until the end of the study. They were examined frequently for clinical signs of any adverse, drug-related side effects. Acceptable toxicity for cancer drugs in mice is defined by the NCI as a mean group weight loss of less than 20% during  
30 the test, and not more than one toxic death among ten treated animals.

### Statistics and Graphical Analyses

The unpaired t-test and Mann-Whitney U-test (for analysis of means and medians, respectively) were used to determine the statistical significance of the difference in mean tumor weights for mice in a treatment group and mice in a control group. The two-tailed statistical analyses were conducted at  $P = 0.05$ .

### Results

#### Efficacy: Growth of HT29 Colon Carcinomas in Control Mice

Treatment protocols are listed in Table 3. Group 1 mice received no treatment and served as controls for CPT-11 and 5D5 therapy. Group 3 mice received fifteen 75  $\mu$ g/mouse doses of irrelevant mouse IgG on alternate days (qod x 15). Table 4 summarizes the results for all groups in the study. The mean values for actual day 31 tumor weights in untreated and IgG-treated mice are 640.0 and 696.2 mg, respectively.

Table 4. Treatment Response Summary for the HT29-e28 Study

Gp		Regimen I				Final Tumor Weight Mean $\pm$ SEM (n)	Tumor Growth Inhibition	# CP	Mean % Tumor Decrease	# CR	Max. % BW Loss Day	# Death*	
		Agent	mg/kg	Route	Schedule							TR	NT R
1	10	No treatment	n/a			640.0 $\pm$ 124.9 mg (10)	0%	0	None	0	-0.4%; Day 4	0	0
2	10	CPT-11	100	IP	Qwk x 3	447.9 $\pm$ 91.8 mg (10)	34.7%	0	None	0	-5.8%; Day4	0	0
3	10	Control IgG	75 $\mu$ g/ mouse	IV	Qod x 15	696.2 $\pm$ 131.4 mg (10)	0%	0	None	0	-3.6%; Day 4	0	0
4	10	5D5	75 $\mu$ g/ mouse	IV	Qod x 15	543.5 $\pm$ 149.3 mg (8)	17.8%		None	0	-2.0%; Day 4	0	0
5	10	5D5	25 $\mu$ g/ mouse	IV	Qod x 15	700.7 $\pm$ 116.1 mg (10) ~	0%	0	None	0	-1.2%; Day4	0	0



*Response of HT29 Xenografts to Intraperitoneal CPT-11 Therapy*

Group 2 mice were treated once weekly for three weeks (qwk x 3) with i.p. injections of 100 mg/kg CPT-11 (Table 3). No tumors regressed in response to CPT-11. The final mean tumor weight in Group 3 mice was 447.9 mg (Table 4). Group 2 mice experienced 34.7% tumor growth inhibition, relative to the untreated mice. This result, which is illustrated in a bar graph in **FIGURE 3**, was not statistically significant ( $P = 0.23.11$ , unpaired two-tailed t-test). **FIGURES 4A-E** shows the growth of individual tumors in all treatment groups, as calculated from caliper measurements. CPT-11 treatment caused a decrease in the slope of tumor growth.

*Response of HT29 Xenografts to Intravenous 5D5 Immunotherapy*

5D5 was administered intravenously to mice in Groups 4 and 5 on the qod x 15 schedule at 75 and 25 ug/mouse, respectively (Table 3). No tumor regressions were observed. The 75 and 25 ug/mg mouse 5D5 treatments yielded final actual mean tumor weights of 543.5 and 700.7, respectively (Table 4). The high dose of 5D5 inhibited HT29 carcinoma growth by 17.8%, relative to tumor growth in untreated mice. Tumor growth inhibition in Group 4 mice, relative to untreated and IgG-treated mice, was not statistically significant ( $P = 0.6241$  and  $0.453$ , respectively; t-test). Group 5 mice experienced no inhibition of tumor growth. **FIGURE 3** illustrates the lack of significant tumor growth inhibition, given the large error (SEM) bars. **FIGURES 4 A-E** shows that there was a modest decrease in the slopes of the tumor growth curves in animals treated with 75 ug/mouse 5D5.

*Side Effects*

All therapies were well tolerated. The highest group mean body-weight loss, an acceptable 5.8%, was recorded in mice treated with CPT-11. Body weight losses in antibody-treated mice were 3.6% or lower.

*Discussion*

The HT29 colon carcinoma xenograft model was appropriate for 5D5 evaluation because HT29 cells produce laminin. Growth of primary tumors can be impeded by anti-proliferative agents, such as CPT-11, as well as by agents that prevent invasion of the substratum. Combinational

treatments using monoclonal antibodies against the  $\gamma 2$  chain of laminin-5, such as 5D5, with anti-proliferative agents such as CPT-11 are also contemplated as part of the invention. Treatment efficacy was based on tumor growth inhibition, i.e., the difference between the mean increase in tumor size in control and treated groups of animals during the 31-day study. Although there was no response to 5D5 at a dose of 25  $\mu\text{g}/\text{mouse}$ , tumor growth was inhibited by 17.8% at 75  $\mu\text{g}/\text{mouse}$  (Table 4 and FIGURE 3). Thus, a 75  $\mu\text{g}/\text{mouse}$  dose of 5D5 produced some therapeutic effect against HT29 colon carcinomas. In general, there was a reduction in the slopes of the tumor growth curves in mice treated with CPT-11 and 5D5 (FIGURES 4A-E). Accordingly, these results indicate that anti-laminin immunotherapy has application in cancer treatment of laminin-5 secreting tumors.


in summary, established HT29 colon carcinomas responded to therapy with 75  $\mu\text{g}/\text{mouse}$  doses of 5D5. High dose 5D5 immunotherapy achieved 50% of the tumor growth inhibition that was produced by CPT-11 chemotherapy. The tumor growth shown in FIGURES 4A-E curves suggest that 5D5 immunotherapy can impair colon tumor growth at doses of 75  $\mu\text{g}/\text{mouse}$  or higher.



Those skilled in the art will know, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. These and all other equivalents are intended to be encompassed by the following claims.

We claim:

1. Use of an antibody that binds to one or more epitopes of a laminin 5  $\gamma$ 2 chain for the preparation of a medicament for inhibiting tumor growth in a patient with a tumor.
2. The use of claim 1 wherein the antibody is a monoclonal antibody.
- 5 3. The use of claim 1 or 2 wherein the tumor is a carcinoma.
4. The use of any one of claims 1-3 wherein the medicament further comprises one or more further anti-tumor agent.
5. The use of claim 4 wherein the further anti-tumor agent is a chemotherapeutic agent.
6. An isolated antibody that binds to one or one or more epitopes of domain III of the  
10 laminin 5  $\gamma$ 2 chain but does not bind to epitopes within the amino acid sequence of  
**SEQ ID NOS: 9 and 10.**
7. The isolated antibody of claim 5 wherein the antibody is a monoclonal antibody.
8. A pharmaceutical composition comprising the isolated antibody of claim 5 and a pharmaceutically acceptable carrier.
- 15 9. Isolated hybridoma cells that express the monoclonal antibody of claim 6.
10. Use of the isolated antibody of any one of claims 6-8 for the preparation of a medicament for one or more of inhibiting tumor growth, inhibiting tumor metastasis, and detecting invasive cells in a patient with a tumor.
11. A pharmaceutical composition comprising an antibody that binds to one or more  
20 epitopes in domain III of laminin 5  $\gamma$ 2 chain and a further anti-tumor agent.
12. The pharmaceutical composition of claim 6 wherein the further anti-tumor agent is a chemotherapeutic agent.
13. A method for detecting the presence of invasive cells in a tissue comprising  
25 contacting the tissue sample with the antibody of any one of claims 6-8 to form an immunocomplex, and detecting formation of the immunocomplex, wherein the formation of the immunocomplex correlates with the presence of invasive cells in the tissue.


30

*FIG. 1*

*FIG. 2A**FIG. 2B*

*FIG. 3*

TUMOR GROWTH INHIBITION ON DAY 31  
IN THE HT29-e28 STUDY






FIGURE 4A

**Tumor Growth Curves for Individual Mice in the HT29-e28 Study**  
Group 2: CPT-11: 100 mg/kg; ip; qwik x 3




FIGURE 4B



**Tumor Growth Curves for Individual Mice in the HT29-e28 Study**  
Group 3: Control IgG; 75 mg/kg; IV; qod x 15




FIGURE 4C

**Tumor Growth Curves for Individual Mice in the HT29-e28 Study**  
Group 4: UD2; 75 mg/kg; iv; qod x 15




FIGURE 4D

# **Tumor Growth Curves for Individual Mice in the HT29-e28 Study** Group 5: UD2; 25 mg/kg; iv; qod x 15




FIGURE 4E

## SEQUENCE LISTING

<110> Tryggvason, Karl  
Salo, Sirpa

<120> Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis

<130> 02-1147-PCT

<150> 60/422,009

<151> 2002-10-29

<160> 10

<170> PatentIn version 3.1

<210> 1

<211> 5200

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (118)..(3699)

<223>

<220>

<221> sig\_peptide

<222> (118)..(183)

<223>

<400> 1

gaccacctga tcgaaggaaa aggaaggcac agcggagcgc agagtgagaa ccaccaaccg	60
aggcgccggg cagcgacccc tgcagcggag acagagactg agcggcccg caccgcc	117
atg cct gcg ctc tgg ctg ggc tgc tgc ctc tgc ttc tcg ctc ctc ctg	165
Met Pro Ala Leu Trp Leu Gly Cys Cys Leu Cys Phe Ser Leu Leu Leu	
1 5 10 15	
ccc gca gcc cgg gcc acc tcc agg agg gaa gtc tgt gat tgc aat ggg	213
Pro Ala Ala Arg Ala Thr Ser Arg Arg Glu Val Cys Asp Cys Asn Gly	
20 25 30	
aag tcc agg cag tgt atc ttt gat cgg gaa ctt cac aga caa act ggt	261
Lys Ser Arg Gln Cys Ile Phe Asp Arg Glu Leu His Arg Gln Thr Gly	
35 40 45	
aat gga ttc cgc tgc ctc aac tgc aat gac aac act gat ggc att cac	309
Asn Gly Phe Arg Cys Leu Asn Cys Asn Asp Asn Thr Asp Gly Ile His	
50 55 60	
tgc gag aag tgc aag aat ggc ttt tac cgg cac aga gaa agg gac cgc	357
Cys Glu Lys Cys Lys Asn Gly Phe Tyr Arg His Arg Glu Arg Asp Arg	
65 70 75 80	
tgt ttg ccc tgc aat tgt aac tcc aaa ggt tct ctt agt gct cga tgt	405
Cys Leu Pro Cys Asn Cys Asn Ser Lys Gly Ser Leu Ser Ala Arg Cys	
85 90 95	
gac aac tct gga cgg tgc agc tgt aaa cca ggt gtg aca gga gcc aga	453
Asp Asn Ser Gly Arg Cys Ser Cys Lys Pro Gly Val Thr Gly Ala Arg	

100	105	110	
tgc gac cga tgt ctg cca ggc ttc cac atg ctc acg gat gcg ggg tgc Cys Asp Arg Cys Leu Pro Gly Phe His Met Leu Thr Asp Ala Gly Cys 115 120 125			501
acc caa gac cag aga ctg cta gac tcc aag tgt gac tgt gac cca gct Thr Gln Asp Gln Arg Leu Leu Asp Ser Lys Cys Asp Cys Asp Pro Ala 130 135 140			549
ggc atc gca ggg ccc tgt gac gcg ggc cgc tgt gtc tgc aag cca gct Gly Ile Ala Gly Pro Cys Asp Ala Gly Arg Cys Val Cys Lys Pro Ala 145 150 155 160			597
gtt act gga gaa cgc tgt gat agg tgt cga tca ggt tac tat aat ctg Val Thr Gly Glu Arg Cys Asp Arg Cys Arg Ser Gly Tyr Tyr Asn Leu 165 170 175			645
gat ggg ggg aac cct gag ggc tgt acc cag tgt ttc tgc tat ggg cat Asp Gly Gly Asn Pro Glu Gly Cys Thr Gln Cys Phe Cys Tyr Gly His 180 185 190			693
tca gcc agc tgc cgc agc tct gca gaa tac agt gtc cat aag atc acc Ser Ala Ser Cys Arg Ser Ser Ala Glu Tyr Ser Val His Lys Ile Thr 195 200 205			741
tct acc ttt cat caa gat gtt gat ggc tgg aag gct gtc caa cga aat Ser Thr Phe His Gln Asp Val Asp Gly Trp Lys Ala Val Gln Arg Asn 210 215 220			789
ggg tct cct gca aag ctc caa tgg tca cag cgc cat caa gat gtg ttt Gly Ser Pro Ala Lys Leu Gln Trp Ser Gln Arg His Gln Asp Val Phe 225 230 235 240			837
agc tca gcc caa cga cta gat cct gtc tat ttt gtg gct cct gcc aaa Ser Ser Ala Gln Arg Leu Asp Pro Val Tyr Phe Val Ala Pro Ala Lys 245 250 255			885
ttt ctt ggg aat caa cag gtg agc tat ggg caa agc ctg tcc ttt gac Phe Leu Gly Asn Gln Gln Val Ser Tyr Gly Gln Ser Leu Ser Phe Asp 260 265 270			933
tac cgt gtg gac aga gga ggc aga cac cca tct gcc cat gat gtg atc Tyr Arg Val Asp Arg Gly Gly Arg His Pro Ser Ala His Asp Val Ile 275 280 285			981
ctg gaa ggt gct ggt cta cgg atc aca gct ccc ttg atg cca ctt ggc Leu Glu Gly Ala Gly Leu Arg Ile Thr Ala Pro Leu Met Pro Leu Gly 290 295 300			1029
aag aca ctg cct tgt ggg ctc acc aag act tac aca ttc agg tta aat Lys Thr Leu Pro Cys Gly Leu Thr Lys Thr Tyr Thr Phe Arg Leu Asn 305 310 315 320			1077
gag cat cca agc aat aat tgg agc ccc cag ctg agt tac ttt gag tat Glu His Pro Ser Asn Asn Trp Ser Pro Gln Leu Ser Tyr Phe Glu Tyr 325 330 335			1125
cga agg tta ctg cgg aat ctc aca gcc ctc cgc atc cga gct aca tat Arg Arg Leu Leu Arg Asn Leu Thr Ala Leu Arg Ile Arg Ala Thr Tyr 340 345 350			1173
gga gaa tac agt act ggg tac att gac aat gtg acc ctg att tca gcc			1221

3/25

Gly	Glu	Tyr	Ser	Thr	Gly	Tyr	Ile	Asp	Asn	Val	Thr	Leu	Ile	Ser	Ala		
		355					360					365					
cgc	cct	gtc	tct	gga	gcc	cca	gca	ccc	tgg	gtt	gaa	cag	tgt	ata	tgt		1269
Arg	Pro	Val	Ser	Gly	Ala	Pro	Ala	Pro	Trp	Val	Glu	Gln	Cys	Ile	Cys		
		370					375				380						
cct	gtt	ggg	tac	aag	ggg	caa	ttc	tgc	cag	gat	tgt	gct	tct	ggc	tac		1317
Pro	Val	Gly	Tyr	Lys	Gly	Gln	Phe	Cys	Gln	Asp	Cys	Ala	Ser	Gly	Tyr		
		385				390				395					400		
aag	aga	gat	tca	gcg	aga	ctg	ggg	cct	ttt	ggc	acc	tgt	att	cct	tgt		1365
Lys	Arg	Asp	Ser	Ala	Arg	Leu	Gly	Pro	Phe	Gly	Thr	Cys	Ile	Pro	Cys		
				405					410					415			
aac	tgt	caa	ggg	gga	ggg	gcc	tgt	gat	cca	gac	aca	gga	gat	tgt	tat		1413
Asn	Cys	Gln	Gly	Gly	Gly	Ala	Cys	Asp	Pro	Asp	Thr	Gly	Asp	Cys	Tyr		
			420					425						430			
tca	ggg	gat	gag	aat	cct	gac	att	gag	tgt	gct	gac	tgc	cca	att	ggg		1461
Ser	Gly	Asp	Glu	Asn	Pro	Asp	Ile	Glu	Cys	Ala	Asp	Cys	Pro	Ile	Gly		
		435					440					445					
ttc	tac	aac	gat	ccg	cac	gac	ccc	cgc	agc	tgc	aag	cca	tgt	ccc	tgt		1509
Phe	Tyr	Asn	Asp	Pro	His	Asp	Pro	Arg	Ser	Cys	Lys	Pro	Cys	Pro	Cys		
		450				455					460						
cat	aac	ggg	ttc	agc	tgc	tca	gtg	att	ccg	gag	acg	gag	gag	gtg	gtg		1557
His	Asn	Gly	Phe	Ser	Cys	Ser	Val	Ile	Pro	Glu	Thr	Glu	Glu	Val	Val		
					470					475					480		
tgc	aat	aac	tgc	cct	ccc	ggg	gtc	acc	ggg	gcc	cgc	tgt	gag	ctc	tgt		1605
Cys	Asn	Asn	Cys	Pro	Pro	Gly	Val	Thr	Gly	Ala	Arg	Cys	Glu	Leu	Cys		
				485					490					495			
gct	gat	ggc	tac	ttt	ggg	gac	ccc	ttt	ggg	gaa	cat	ggc	cca	gtg	agg		1653
Ala	Asp	Gly	Tyr	Phe	Gly	Asp	Pro	Phe	Gly	Glu	His	Gly	Pro	Val	Arg		
			500					505					510				
cct	tgt	cag	ccc	tgt	caa	tgc	aac	agc	aat	gtg	gac	ccc	agt	gcc	tct		1701
Pro	Cys	Gln	Pro	Cys	Gln	Cys	Asn	Ser	Asn	Val	Asp	Pro	Ser	Ala	Ser		
		515					520					525					
ggg	aat	tgt	gac	cgg	ctg	aca	ggc	agg	tgt	ttg	aag	tgt	atc	cac	aac		1749
Gly	Asn	Cys	Asp	Arg	Leu	Thr	Gly	Arg	Cys	Leu	Lys	Cys	Ile	His	Asn		
		530				535					540						
aca	gcc	ggc	atc	tac	tgc	gac	cag	tgc	aaa	gca	ggc	tac	ttc	ggg	gac		1797
Thr	Ala	Gly	Ile	Tyr	Cys	Asp	Gln	Cys	Lys	Ala	Gly	Tyr	Phe	Gly	Asp		
					550					555					560		
cca	ttg	gct	ccc	aac	cca	gca	gac	aag	tgt	cga	gct	tgc	aac	tgt	aac		1845
Pro	Leu	Ala	Pro	Asn	Pro	Ala	Asp	Lys	Cys	Arg	Ala	Cys	Asn	Cys	Asn		
				565					570					575			
ccc	atg	ggc	tca	gag	cct	gta	gga	tgt	cga	agt	gat	ggc	acc	tgt	gtt		1893
Pro	Met	Gly	Ser	Glu	Pro	Val	Gly	Cys	Arg	Ser	Asp	Gly	Thr	Cys	Val		
				580				585					590				
tgc	aag	cca	gga	ttt	ggg	ggc	ccc	aac	tgt	gag	cat	gga	gca	ttc	agc		1941
Cys	Lys	Pro	Gly	Phe	Gly	Gly	Pro	Asn	Cys	Glu	His	Gly	Ala	Phe	Ser		
			595				600						605				

tgt cca gct tgc tat aat caa gtg aag att cag atg gat cag ttt atg	1989
Cys Pro Ala Cys Tyr Asn Gln Val Lys Ile Gln Met Asp Gln Phe Met	
610 615 620	
cag cag ctt cag aga atg gag gcc ctg att tca aag gct cag ggt ggt	2037
Gln Gln Leu Gln Arg Met Glu Ala Leu Ile Ser Lys Ala Gln Gly Gly	
625 630 635 640	
gat gga gta gta cct gat aca gag ctg gaa ggc agg atg cag cag gct	2085
Asp Gly Val Val Pro Asp Thr Glu Leu Glu Gly Arg Met Gln Gln Ala	
645 650 655	
gag cag gcc ctt cag gac att ctg aga gat gcc cag att tca gaa ggt	2133
Glu Gln Ala Leu Gln Asp Ile Leu Arg Asp Ala Gln Ile Ser Glu Gly	
660 665 670	
gct agc aga tcc ctt ggt ctc cag ttg gcc aag gtg agg agc caa gag	2181
Ala Ser Arg Ser Leu Gly Leu Gln Leu Ala Lys Val Arg Ser Gln Glu	
675 680 685	
aac agc tac cag agc cgc ctg gat gac ctc aag atg act gtg gaa aga	2229
Asn Ser Tyr Gln Ser Arg Leu Asp Asp Leu Lys Met Thr Val Glu Arg	
690 695 700	
gtt cgg gct ctg gga agt cag tac cag aac cga gtt cgg gat act cac	2277
Val Arg Ala Leu Gly Ser Gln Tyr Gln Asn Arg Val Arg Asp Thr His	
705 710 715 720	
agg ctc atc act cag atg cag ctg agc ctg gca gaa agt gaa gct tcc	2325
Arg Leu Ile Thr Gln Met Gln Leu Ser Leu Ala Glu Ser Glu Ala Ser	
725 730 735	
ttg gga aac act aac att cct gcc tca gac cac tac gtg ggg cca aat	2373
Leu Gly Asn Thr Asn Ile Pro Ala Ser Asp His Tyr Val Gly Pro Asn	
740 745 750	
ggc ttt aaa agt ctg gct cag gag gcc aca aga tta gca gaa agc cac	2421
Gly Phe Lys Ser Leu Ala Gln Glu Ala Thr Arg Leu Ala Glu Ser His	
755 760 765	
gtt gag tca gcc agt aac atg gag caa ctg aca agg gaa act gag gac	2469
Val Glu Ser Ala Ser Asn Met Glu Gln Leu Thr Arg Glu Thr Glu Asp	
770 775 780	
tat tcc aaa caa gcc ctc tca ctg gtg cgc aag gcc ctg cat gaa gga	2517
Tyr Ser Lys Gln Ala Leu Ser Leu Val Arg Lys Ala Leu His Glu Gly	
785 790 795 800	
gtc gga agc gga agc ggt agc ccg gac ggt gct gtg gtg caa ggg ctt	2565
Val Gly Ser Gly Ser Pro Asp Gly Ala Val Val Gln Gly Leu	
805 810 815	
gtg gaa aaa ttg gag aaa acc aag tcc ctg gcc cag cag ttg aca agg	2613
Val Glu Lys Leu Glu Lys Thr Lys Ser Leu Ala Gln Gln Leu Thr Arg	
820 825 830	
gag gcc act caa gcg gaa att gaa gca gat agg tct tat cag cac agt	2661
Glu Ala Thr Gln Ala Glu Ile Glu Ala Asp Arg Ser Tyr Gln His Ser	
835 840 845	
ctc cgc ctc ctg gat tca gtg tct ccg ctt cag gga gtc agt gat cag	2709
Leu Arg Leu Leu Asp Ser Val Ser Pro Leu Gln Gly Val Ser Asp Gln	
850 855 860	

tcc ttt cag gtg gaa gaa gca aag agg atc aaa caa aaa gcg gat tca	2757
Ser Phe Gln Val Glu Glu Ala Lys Arg Ile Lys Gln Lys Ala Asp Ser	
865 870 875 880	
ctc tca agc ctg gta acc agg cat atg gat gag ttc aag cgt aca caa	2805
Leu Ser Ser Leu Val Thr Arg His Met Asp Glu Phe Lys Arg Thr Gln	
885 890 895	
aag aat ctg gga aac tgg aaa gaa gaa gca cag cag ctc tta cag aat	2853
Lys Asn Leu Gly Asn Trp Lys Glu Glu Ala Gln Gln Leu Leu Gln Asn	
900 905 910	
gga aaa agt ggg aga gag aaa tca gat cag ctg ctt tcc cgt gcc aat	2901
Gly Lys Ser Gly Arg Glu Lys Ser Asp Gln Leu Leu Ser Arg Ala Asn	
915 920 925	
ctt gct aaa agc aga gca caa gaa gca ctg agt atg ggc aat gcc act	2949
Leu Ala Lys Ser Arg Ala Gln Glu Ala Leu Ser Met Gly Asn Ala Thr	
930 935 940	
ttt tat gaa gtt gag agc atc ctt aaa aac ctc aga gag ttt gac ctg	2997
Phe Tyr Glu Val Glu Ser Ile Leu Lys Asn Leu Arg Glu Phe Asp Leu	
945 950 955 960	
cag gtg gac aac aga aaa gca gaa gct gaa gaa gcc atg aag aga ctc	3045
Gln Val Asp Asn Arg Lys Ala Glu Ala Glu Glu Ala Met Lys Arg Leu	
965 970 975	
tcc tac atc agc cag aag gtt tca gat gcc agt gac aag acc cag caa	3093
Ser Tyr Ile Ser Gln Lys Val Ser Asp Ala Ser Asp Lys Thr Gln Gln	
980 985 990	
gca gaa aga gcc ctg ggg agc gct gct gct gat gca cag agg gca aag	3141
Ala Glu Arg Ala Leu Gly Ser Ala Ala Ala Asp Ala Gln Arg Ala Lys	
995 1000 1005	
aat ggg gcc ggg gag gcc ctg gaa atc tcc agt gag att gaa cag	3186
Asn Gly Ala Gly Glu Ala Leu Glu Ile Ser Ser Glu Ile Glu Gln	
1010 1015 1020	
gag att ggg agt ctg aac ttg gaa gcc aat gtg aca gca gat gga	3231
Glu Ile Gly Ser Leu Asn Leu Glu Ala Asn Val Thr Ala Asp Gly	
1025 1030 1035	
gcc ttg gcc atg gaa aag gga ctg gcc tct ctg aag agt gag atg	3276
Ala Leu Ala Met Glu Lys Gly Leu Ala Ser Leu Lys Ser Glu Met	
1040 1045 1050	
agg gaa gtg gaa gga gag ctg gaa agg aag gag ctg gag ttt gac	3321
Arg Glu Val Glu Gly Glu Leu Glu Arg Lys Glu Leu Glu Phe Asp	
1055 1060 1065	
acg aat atg gat gca gta cag atg gtg att aca gaa gcc cag aag	3366
Thr Asn Met Asp Ala Val Gln Met Val Ile Thr Glu Ala Gln Lys	
1070 1075 1080	
gtt gat acc aga gcc aag aac gct ggg gtt aca atc caa gac aca	3411
Val Asp Thr Arg Ala Lys Asn Ala Gly Val Thr Ile Gln Asp Thr	
1085 1090 1095	
ctc aac aca tta gac ggc ctc ctg cat ctg atg gac cag cct ctc	3456
Leu Asn Thr Leu Asp Gly Leu Leu His Leu Met Asp Gln Pro Leu	



1100	1105	1110	
agt gta gat gaa gag ggg ctg gtc tta ctg gag cag aag ctt tcc 3501			
Ser Val Asp Glu Glu Gly Leu Val Leu Leu Glu Gln Lys Leu Ser			
1115 1120 1125			
cga gcc aag acc cag atc aac agc caa ctg cgg ccc atg atg tca 3546			
Arg Ala Lys Thr Gln Ile Asn Ser Gln Leu Arg Pro Met Met Ser			
1130 1135 1140			
gag ctg gaa gag agg gca cgt cag cag agg ggc cac ctc cat ttg 3591			
Glu Leu Glu Glu Arg Ala Arg Gln Gln Arg Gly His Leu His Leu			
1145 1150 1155			
ctg gag aca agc ata gat ggg att ctg gct gat gtg aag aac ttg 3636			
Leu Glu Thr Ser Ile Asp Gly Ile Leu Ala Asp Val Lys Asn Leu			
1160 1165 1170			
gag aac att agg gac aac ctg ccc cca ggc tgc tac aat acc cag 3681			
Glu Asn Ile Arg Asp Asn Leu Pro Pro Gly Cys Tyr Asn Thr Gln			
1175 1180 1185			
gct ctt gag caa cag tga agctgccata aatattttctc aactgaggtt 3729			
Ala Leu Glu Gln Gln			
1190			
cttgggatac agatctcagg gctcgggagc catgtcatgt gagtgggtgg gatggggaca 3789			
tttgaacatg tttaatgggt atgctcaggt caactgacct gaccccatc ctgatcccat 3849			
ggccaggtgg ttgtcttatt gcaccatact ccttgcttcc tgatgctggg catgaggcag 3909			
ataggcactg gtgtgagaat gatcaaggat ctggacccca aagatagact ggatggaaag 3969			
acaaactgca caggcagatg tttgcctcat aatagtcgta agtggagtcc tggaatttgg 4029			
acaagtgctg ttgggatata gtcaacttat tctttgagta atgtgactaa aggaaaaaac 4089			
tttgactttg cccaggcatg aaattcttcc taatgtcaga acagagtgca acccagtcac 4149			
actgtggcca gtaaaatact attgcctcat attgtcctct gcaagcttct tgctgatcag 4209			
agttcctcct acttacaacc cagggtgtga acatgttctc cattttcaag ctggaagaag 4269			
tgagcagtgt tggagtgagg acctgtaagg caggcccatc cagagctatg gtgcttgctg 4329			
gtgcctgcca ccttcaagtt ctggacctgg gcatgacatc ctttctttta atgatgccat 4389			
ggcaacttag agattgcatt tttattaaag catttcctac cagcaaagca aatgttggga 4449			
aagtatttac tttttcggtt tcaaagtgat agaaaagtgt ggcttgggca ttgaaagagg 4509			
taaaattctc tagatttatt agtcctaatt caatcctact tttcgaacac caaaaatgat 4569			
gogcatcaat gtattttatc ttattttctc aatctcctct ctctttcctc caccataat 4629			
aagagaatgt tcctactcac acttcagctg ggtcacatcc atccctccat tcctccttcc 4689			
atccatcttt ccatccatta cctccatcca tccttccaac atatatttat tgagtaccta 4749			
ctgtgtgcca ggggctggtg ggacagtggg gacatagtct ctgccctcat agagttgatt 4809			
gtctagttag gaagacaagc atttttaaaa aataaattta aacttacaaa ctttgtttgt 4869			

cacaagtgggt gtttattgca ataaccgctt ggtttgcaac ctctttgctc aacagaacat 4929  
 atgttgcaag accctcccat gggcactgag tttggcaagg atgacagagc tctgggttgt 4989  
 gcacatttct ttgcattcca gcgtcactct gtgccttcta caactgattg caacagactg 5049  
 ttgagttatg ataacaccag tgggaattgc tggaggaacc agaggcactt ccaccttggc 5109  
 tgggaagact atggtgctgc cttgcttctg tatttccttg gattttcctg aaagtgtttt 5169  
 taaataaaga acaattgtta gatgccaaaa a 5200

<210> 2  
 <211> 1193  
 <212> PRT  
 <213> Homo sapiens

<400> 2

Met Pro Ala Leu Trp Leu Gly Cys Cys Leu Cys Phe Ser Leu Leu Leu  
 1 5 10 15

Pro Ala Ala Arg Ala Thr Ser Arg Arg Glu Val Cys Asp Cys Asn Gly  
 20 25 30

Lys Ser Arg Gln Cys Ile Phe Asp Arg Glu Leu His Arg Gln Thr Gly  
 35 40 45

Asn Gly Phe Arg Cys Leu Asn Cys Asn Asp Asn Thr Asp Gly Ile His  
 50 55 60

Cys Glu Lys Cys Lys Asn Gly Phe Tyr Arg His Arg Glu Arg Asp Arg  
 65 70 75 80

Cys Leu Pro Cys Asn Cys Asn Ser Lys Gly Ser Leu Ser Ala Arg Cys  
 85 90 95

Asp Asn Ser Gly Arg Cys Ser Cys Lys Pro Gly Val Thr Gly Ala Arg  
 100 105 110

Cys Asp Arg Cys Leu Pro Gly Phe His Met Leu Thr Asp Ala Gly Cys  
 115 120 125

Thr Gln Asp Gln Arg Leu Leu Asp Ser Lys Cys Asp Cys Asp Pro Ala  
 130 135 140

Gly Ile Ala Gly Pro Cys Asp Ala Gly Arg Cys Val Cys Lys Pro Ala  
 145 150 155 160

Val Thr Gly Glu Arg Cys Asp Arg Cys Arg Ser Gly Tyr Tyr Asn Leu  
 165 170 175

Asp Gly Gly Asn Pro Glu Gly Cys Thr Gln Cys Phe Cys Tyr Gly His  
 180 185 190

Ser Ala Ser Cys Arg Ser Ser Ala Glu Tyr Ser Val His Lys Ile Thr  
 195 200 205

Ser Thr Phe His Gln Asp Val Asp Gly Trp Lys Ala Val Gln Arg Asn  
 210 215 220

Gly Ser Pro Ala Lys Leu Gln Trp Ser Gln Arg His Gln Asp Val Phe  
 225 230 235 240

Ser Ser Ala Gln Arg Leu Asp Pro Val Tyr Phe Val Ala Pro Ala Lys  
 245 250 255

Phe Leu Gly Asn Gln Gln Val Ser Tyr Gly Gln Ser Leu Ser Phe Asp  
 260 265 270

Tyr Arg Val Asp Arg Gly Gly Arg His Pro Ser Ala His Asp Val Ile  
 275 280 285

Leu Glu Gly Ala Gly Leu Arg Ile Thr Ala Pro Leu Met Pro Leu Gly  
 290 295 300

Lys Thr Leu Pro Cys Gly Leu Thr Lys Thr Tyr Thr Phe Arg Leu Asn  
 305 310 315 320

Glu His Pro Ser Asn Asn Trp Ser Pro Gln Leu Ser Tyr Phe Glu Tyr  
 325 330 335

Arg Arg Leu Leu Arg Asn Leu Thr Ala Leu Arg Ile Arg Ala Thr Tyr  
 340 345 350

Gly Glu Tyr Ser Thr Gly Tyr Ile Asp Asn Val Thr Leu Ile Ser Ala  
 355 360 365

Arg Pro Val Ser Gly Ala Pro Ala Pro Trp Val Glu Gln Cys Ile Cys  
 370 375 380

Pro Val Gly Tyr Lys Gly Gln Phe Cys Gln Asp Cys Ala Ser Gly Tyr  
 385 390 395 400

Lys Arg Asp Ser Ala Arg Leu Gly Pro Phe Gly Thr Cys Ile Pro Cys  
 405 410 415

Asn Cys Gln Gly Gly Gly Ala Cys Asp Pro Asp Thr Gly Asp Cys Tyr

420

425

430

Ser Gly Asp Glu Asn Pro Asp Ile Glu Cys Ala Asp Cys Pro Ile Gly  
 435 440 445

Phe Tyr Asn Asp Pro His Asp Pro Arg Ser Cys Lys Pro Cys Pro Cys  
 450 455 460

His Asn Gly Phe Ser Cys Ser Val Ile Pro Glu Thr Glu Glu Val Val  
 465 470 475 480

Cys Asn Asn Cys Pro Pro Gly Val Thr Gly Ala Arg Cys Glu Leu Cys  
 485 490 495

Ala Asp Gly Tyr Phe Gly Asp Pro Phe Gly Glu His Gly Pro Val Arg  
 500 505 510

Pro Cys Gln Pro Cys Gln Cys Asn Ser Asn Val Asp Pro Ser Ala Ser  
 515 520 525

Gly Asn Cys Asp Arg Leu Thr Gly Arg Cys Leu Lys Cys Ile His Asn  
 530 535 540

Thr Ala Gly Ile Tyr Cys Asp Gln Cys Lys Ala Gly Tyr Phe Gly Asp  
 545 550 555 560

Pro Leu Ala Pro Asn Pro Ala Asp Lys Cys Arg Ala Cys Asn Cys Asn  
 565 570 575

Pro Met Gly Ser Glu Pro Val Gly Cys Arg Ser Asp Gly Thr Cys Val  
 580 585 590

Cys Lys Pro Gly Phe Gly Gly Pro Asn Cys Glu His Gly Ala Phe Ser  
 595 600 605

Cys Pro Ala Cys Tyr Asn Gln Val Lys Ile Gln Met Asp Gln Phe Met  
 610 615 620

Gln Gln Leu Gln Arg Met Glu Ala Leu Ile Ser Lys Ala Gln Gly Gly  
 625 630 635 640

Asp Gly Val Val Pro Asp Thr Glu Leu Glu Gly Arg Met Gln Gln Ala  
 645 650 655

Glu Gln Ala Leu Gln Asp Ile Leu Arg Asp Ala Gln Ile Ser Glu Gly  
 660 665 670

10/25

Ala Ser Arg Ser Leu Gly Leu Gln Leu Ala Lys Val Arg Ser Gln Glu  
 675 680 685

Asn Ser Tyr Gln Ser Arg Leu Asp Asp Leu Lys Met Thr Val Glu Arg  
 690 695 700

Val Arg Ala Leu Gly Ser Gln Tyr Gln Asn Arg Val Arg Asp Thr His  
 705 710 715 720

Arg Leu Ile Thr Gln Met Gln Leu Ser Leu Ala Glu Ser Glu Ala Ser  
 725 730 735

Leu Gly Asn Thr Asn Ile Pro Ala Ser Asp His Tyr Val Gly Pro Asn  
 740 745 750

Gly Phe Lys Ser Leu Ala Gln Glu Ala Thr Arg Leu Ala Glu Ser His  
 755 760 765

Val Glu Ser Ala Ser Asn Met Glu Gln Leu Thr Arg Glu Thr Glu Asp  
 770 775 780

Tyr Ser Lys Gln Ala Leu Ser Leu Val Arg Lys Ala Leu His Glu Gly  
 785 790 795 800

Val Gly Ser Gly Ser Gly Ser Pro Asp Gly Ala Val Val Gln Gly Leu  
 805 810 815

Val Glu Lys Leu Glu Lys Thr Lys Ser Leu Ala Gln Gln Leu Thr Arg  
 820 825 830

Glu Ala Thr Gln Ala Glu Ile Glu Ala Asp Arg Ser Tyr Gln His Ser  
 835 840 845

Leu Arg Leu Leu Asp Ser Val Ser Pro Leu Gln Gly Val Ser Asp Gln  
 850 855 860

Ser Phe Gln Val Glu Glu Ala Lys Arg Ile Lys Gln Lys Ala Asp Ser  
 865 870 875 880

Leu Ser Ser Leu Val Thr Arg His Met Asp Glu Phe Lys Arg Thr Gln  
 885 890 895

Lys Asn Leu Gly Asn Trp Lys Glu Glu Ala Gln Gln Leu Leu Gln Asn  
 900 905 910

Gly Lys Ser Gly Arg Glu Lys Ser Asp Gln Leu Leu Ser Arg Ala Asn  
 915 920 925

11/25

Leu Ala Lys Ser Arg Ala Gln Glu Ala Leu Ser Met Gly Asn Ala Thr  
 930 935 940

Phe Tyr Glu Val Glu Ser Ile Leu Lys Asn Leu Arg Glu Phe Asp Leu  
 945 950 955 960

Gln Val Asp Asn Arg Lys Ala Glu Ala Glu Glu Ala Met Lys Arg Leu  
 965 970 975

Ser Tyr Ile Ser Gln Lys Val Ser Asp Ala Ser Asp Lys Thr Gln Gln  
 980 985 990

Ala Glu Arg Ala Leu Gly Ser Ala Ala Ala Asp Ala Gln Arg Ala Lys  
 995 1000 1005

Asn Gly Ala Gly Glu Ala Leu Glu Ile Ser Ser Glu Ile Glu Gln  
 1010 1015 1020

Glu Ile Gly Ser Leu Asn Leu Glu Ala Asn Val Thr Ala Asp Gly  
 1025 1030 1035

Ala Leu Ala Met Glu Lys Gly Leu Ala Ser Leu Lys Ser Glu Met  
 1040 1045 1050

Arg Glu Val Glu Gly Glu Leu Glu Arg Lys Glu Leu Glu Phe Asp  
 1055 1060 1065

Thr Asn Met Asp Ala Val Gln Met Val Ile Thr Glu Ala Gln Lys  
 1070 1075 1080

Val Asp Thr Arg Ala Lys Asn Ala Gly Val Thr Ile Gln Asp Thr  
 1085 1090 1095

Leu Asn Thr Leu Asp Gly Leu Leu His Leu Met Asp Gln Pro Leu  
 1100 1105 1110

Ser Val Asp Glu Glu Gly Leu Val Leu Leu Glu Gln Lys Leu Ser  
 1115 1120 1125

Arg Ala Lys Thr Gln Ile Asn Ser Gln Leu Arg Pro Met Met Ser  
 1130 1135 1140

Glu Leu Glu Glu Arg Ala Arg Gln Gln Arg Gly His Leu His Leu  
 1145 1150 1155

Leu Glu Thr Ser Ile Asp Gly Ile Leu Ala Asp Val Lys Asn Leu  
 1160 1165 1170

Glu Asn Ile Arg Asp Asn Leu Pro Pro Gly Cys Tyr Asn Thr Gln  
 1175 1180 1185

Ala Leu Glu Gln Gln  
 1190

<210> 3  
 <211> 4316  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> sig\_peptide  
 <222> (118)..(183)  
 <223>

<220>  
 <221> CDS  
 <222> (118)..(3453)  
 <223>

<220>  
 <221> repeat\_unit  
 <222> (4021)..(4316)  
 <223>

<220>  
 <221> polyA\_site  
 <222> (4296)..(4316)  
 <223>

<400> 3  
 gaccaccta tcgaaggaaa aggaaggcac agcggagcgc agagtgagaa ccaccaaccg 60  
 aggcgccggg cagcgacccc tgcagcggag acagagactg agcggcccgg caccgcc 117  
 atg cct gcg ctc tgg ctg ggc tgc tgc ctc tgc ttc tcg ctc ctc ctg 165  
 Met Pro Ala Leu Trp Leu Gly Cys Cys Leu Cys Phe Ser Leu Leu Leu  
 1 5 10 15  
 ccc gca gcc cgg gcc acc tcc agg agg gaa gtc tgt gat tgc aat ggg 213  
 Pro Ala Ala Arg Ala Thr Ser Arg Arg Glu Val Cys Asp Cys Asn Gly  
 20 25 30  
 aag tcc agg cag tgt atc ttt gat cgg gaa ctt cac aga caa act ggt 261  
 Lys Ser Arg Gln Cys Ile Phe Asp Arg Glu Leu His Arg Gln Thr Gly  
 35 40 45  
 aat gga ttc cgc tgc ctc aac tgc aat gac aac act gat ggc att cac 309  
 Asn Gly Phe Arg Cys Leu Asn Cys Asn Asp Asn Thr Asp Gly Ile His  
 50 55 60  
 tgc gag aag tgc aag aat ggc ttt tac cgg cac aga gaa agg gac cgc 357  
 Cys Glu Lys Cys Lys Asn Gly Phe Tyr Arg His Arg Glu Arg Asp Arg  
 65 70 75 80  
 tgt ttg ccc tgc aat tgt aac tcc aaa ggt tct ctt agt gct cga tgt 405  
 Cys Leu Pro Cys Asn Cys Asn Ser Lys Gly Ser Leu Ser Ala Arg Cys  
 85 90 95

gac aac tct gga cgg tgc agc tgt aaa cca ggt gtg aca gga gcc aga Asp Asn Ser Gly Arg Cys Ser Cys Lys Pro Gly Val Thr Gly Ala Arg 100 105 110	453
tgc gac cga tgt ctg cca ggc ttc cac atg ctc acg gat gcg ggg tgc Cys Asp Arg Cys Leu Pro Gly Phe His Met Leu Thr Asp Ala Gly Cys 115 120 125	501
acc caa gac cag aga ctg cta gac tcc aag tgt gac tgt gac cca gct Thr Gln Asp Gln Arg Leu Leu Asp Ser Lys Cys Asp Cys Asp Pro Ala 130 135 140	549
ggc atc gca ggg ccc tgt gac gcg ggc cgc tgt gtc tgc aag cca gct Gly Ile Ala Gly Pro Cys Asp Ala Gly Arg Cys Val Cys Lys Pro Ala 145 150 155 160	597
gtt act gga gaa cgc tgt gat agg tgt cga tca ggt tac tat aat ctg Val Thr Gly Glu Arg Cys Asp Arg Cys Arg Ser Gly Tyr Tyr Asn Leu 165 170 175	645
gat ggg ggg aac cct gag ggc tgt acc cag tgt ttc tgc tat ggg cat Asp Gly Gly Asn Pro Glu Gly Cys Thr Gln Cys Phe Cys Tyr Gly His 180 185 190	693
tca gcc agc tgc cgc agc tct gca gaa tac agt gtc cat aag atc acc Ser Ala Ser Cys Arg Ser Ser Ala Glu Tyr Ser Val His Lys Ile Thr 195 200 205	741
tct acc ttt cat caa gat gtt gat ggc tgg aag gct gtc caa cga aat Ser Thr Phe His Gln Asp Val Asp Gly Trp Lys Ala Val Gln Arg Asn 210 215 220	789
ggg tct cct gca aag ctc caa tgg tca cag cgc cat caa gat gtg ttt Gly Ser Pro Ala Lys Leu Gln Trp Ser Gln Arg His Gln Asp Val Phe 225 230 235 240	837
agc tca gcc caa cga cta gat cct gtc tat ttt gtg gct cct gcc aaa Ser Ser Ala Gln Arg Leu Asp Pro Val Tyr Phe Val Ala Pro Ala Lys 245 250 255	885
ttt ctt ggg aat caa cag gtg agc tat ggg caa agc ctg tcc ttt gac Phe Leu Gly Asn Gln Gln Val Ser Tyr Gly Gln Ser Leu Ser Phe Asp 260 265 270	933
tac cgt gtg gac aga gga ggc aga cac cca tct gcc cat gat gtg atc Tyr Arg Val Asp Arg Gly Gly Arg His Pro Ser Ala His Asp Val Ile 275 280 285	981
ctg gaa ggt gct ggt cta cgg atc aca gct ccc ttg atg cca ctt ggc Leu Glu Gly Ala Gly Leu Arg Ile Thr Ala Pro Leu Met Pro Leu Gly 290 295 300	1029
aag aca ctg cct tgt ggg ctc acc aag act tac aca ttc agg tta aat Lys Thr Leu Pro Cys Gly Leu Thr Lys Thr Tyr Thr Phe Arg Leu Asn 305 310 315 320	1077
gag cat cca agc aat aat tgg agc ccc cag ctg agt tac ttt gag tat Glu His Pro Ser Asn Asn Trp Ser Pro Gln Leu Ser Tyr Phe Glu Tyr 325 330 335	1125
cga agg tta ctg cgg aat ctc aca gcc ctc cgc atc cga gct aca tat Arg Arg Leu Leu Arg Asn Leu Thr Ala Leu Arg Ile Arg Ala Thr Tyr	1173



340	345	350	
gga gaa tac agt act ggg tac att gac aat gtg acc ctg att tca gcc Gly Glu Tyr Ser Thr Gly Tyr Ile Asp Asn Val Thr Leu Ile Ser Ala 355 360 365			1221
cgc cct gtc tct gga gcc cca gca ccc tgg gtt gaa cag tgt ata tgt Arg Pro Val Ser Gly Ala Pro Ala Pro Trp Val Glu Gln Cys Ile Cys 370 375 380			1269
cct gtt ggg tac aag ggg caa ttc tgc cag gat tgt gct tct ggc tac Pro Val Gly Tyr Lys Gly Gln Phe Cys Gln Asp Cys Ala Ser Gly Tyr 385 390 395 400			1317
aag aga gat tca gcg aga ctg ggg cct ttt ggc acc tgt att cct tgt Lys Arg Asp Ser Ala Arg Leu Gly Pro Phe Gly Thr Cys Ile Pro Cys 405 410 415			1365
aac tgt caa ggg gga ggg gcc tgt gat cca gac aca gga gat tgt tat Asn Cys Gln Gly Gly Gly Ala Cys Asp Pro Asp Thr Gly Asp Cys Tyr 420 425 430			1413
tca ggg gat gag aat cct gac att gag tgt gct gac tgc cca att ggt Ser Gly Asp Glu Asn Pro Asp Ile Glu Cys Ala Asp Cys Pro Ile Gly 435 440 445			1461
ttc tac aac gat ccg cac gac ccc cgc agc tgc aag cca tgt ccc tgt Phe Tyr Asn Asp Pro His Asp Pro Arg Ser Cys Lys Pro Cys Pro Cys 450 455 460			1509
cat aac ggg ttc agc tgc tca gtg att ccg gag acg gag gag gtg gtg His Asn Gly Phe Ser Cys Ser Val Ile Pro Glu Thr Glu Glu Val Val 465 470 475 480			1557
tgc aat aac tgc cct ccc ggg gtc acc ggt gcc cgc tgt gag ctc tgt Cys Asn Asn Cys Pro Pro Gly Val Thr Gly Ala Arg Cys Glu Leu Cys 485 490 495			1605
gct gat ggc tac ttt ggg gac ccc ttt ggt gaa cat ggc cca gtg agg Ala Asp Gly Tyr Phe Gly Asp Pro Phe Gly Glu His Gly Pro Val Arg 500 505 510			1653
cct tgt cag ccc tgt caa tgc aac agc aat gtg gac ccc agt gcc tct Pro Cys Gln Pro Cys Gln Cys Asn Ser Asn Val Asp Pro Ser Ala Ser 515 520 525			1701
ggg aat tgt gac cgg ctg aca ggc agg tgt ttg aag tgt atc cac aac Gly Asn Cys Asp Arg Leu Thr Gly Arg Cys Leu Lys Cys Ile His Asn 530 535 540			1749
aca gcc ggc atc tac tgc gac cag tgc aaa gca ggc tac ttc ggg gac Thr Ala Gly Ile Tyr Cys Asp Gln Cys Lys Ala Gly Tyr Phe Gly Asp 545 550 555 560			1797
cca ttg gct ccc aac cca gca gac aag tgt cga gct tgc aac tgt aac Pro Leu Ala Pro Asn Pro Ala Asp Lys Cys Arg Ala Cys Asn Cys Asn 565 570 575			1845
ccc atg ggc tca gag cct gta gga tgt cga agt gat ggc acc tgt gtt Pro Met Gly Ser Glu Pro Val Gly Cys Arg Ser Asp Gly Thr Cys Val 580 585 590			1893
tgc aag cca gga ttt ggt ggc ccc aac tgt gag cat gga gca ttc agc			1941

15/25

Cys	Lys	Pro	Gly	Phe	Gly	Gly	Pro	Asn	Cys	Glu	His	Gly	Ala	Phe	Ser		
		595					600					605					
tgt	cca	gct	tgc	tat	aat	caa	gtg	aag	att	cag	atg	gat	cag	ttt	atg		1989
Cys	Pro	Ala	Cys	Tyr	Asn	Gln	Val	Lys	Ile	Gln	Met	Asp	Gln	Phe	Met		
	610					615					620						
cag	cag	ctt	cag	aga	atg	gag	gcc	ctg	att	tca	aag	gct	cag	ggg	ggg		2037
Gln	Gln	Leu	Gln	Arg	Met	Glu	Ala	Leu	Ile	Ser	Lys	Ala	Gln	Gly	Gly		
	625				630					635					640		
gat	gga	gta	gta	cct	gat	aca	gag	ctg	gaa	ggc	agg	atg	cag	cag	gct		2085
Asp	Gly	Val	Val	Pro	Asp	Thr	Glu	Leu	Glu	Gly	Arg	Met	Gln	Gln	Ala		
				645					650					655			
gag	cag	gcc	ctt	cag	gac	att	ctg	aga	gat	gcc	cag	att	tca	gaa	ggg		2133
Glu	Gln	Ala	Leu	Gln	Asp	Ile	Leu	Arg	Asp	Ala	Gln	Ile	Ser	Glu	Gly		
			660					665					670				
gct	agc	aga	tcc	ctt	ggg	ctc	cag	ttg	gcc	aag	gtg	agg	agc	caa	gag		2181
Ala	Ser	Arg	Ser	Leu	Gly	Leu	Gln	Leu	Ala	Lys	Val	Arg	Ser	Gln	Glu		
		675					680					685					
aac	agc	tac	cag	agc	cgc	ctg	gat	gac	ctc	aag	atg	act	gtg	gaa	aga		2229
Asn	Ser	Tyr	Gln	Ser	Arg	Leu	Asp	Asp	Leu	Lys	Met	Thr	Val	Glu	Arg		
		690				695					700						
gtt	cgg	gct	ctg	gga	agt	cag	tac	cag	aac	cga	gtt	cgg	gat	act	cac		2277
Val	Arg	Ala	Leu	Gly	Ser	Gln	Tyr	Gln	Asn	Arg	Val	Arg	Asp	Thr	His		
	705				710					715					720		
agg	ctc	atc	act	cag	atg	cag	ctg	agc	ctg	gca	gaa	agt	gaa	gct	tcc		2325
Arg	Leu	Ile	Thr	Gln	Met	Gln	Leu	Ser	Leu	Ala	Glu	Ser	Glu	Ala	Ser		
				725					730					735			
ttg	gga	aac	act	aac	att	cct	gcc	tca	gac	cac	tac	gtg	ggg	cca	aat		2373
Leu	Gly	Asn	Thr	Asn	Ile	Pro	Ala	Ser	Asp	His	Tyr	Val	Gly	Pro	Asn		
			740					745					750				
ggc	ttt	aaa	agt	ctg	gct	cag	gag	gcc	aca	aga	tta	gca	gaa	agc	cac		2421
Gly	Phe	Lys	Ser	Leu	Ala	Gln	Glu	Ala	Thr	Arg	Leu	Ala	Glu	Ser	His		
		755					760					765					
gtt	gag	tca	gcc	agt	aac	atg	gag	caa	ctg	aca	agg	gaa	act	gag	gac		2469
Val	Glu	Ser	Ala	Ser	Asn	Met	Glu	Gln	Leu	Thr	Arg	Glu	Thr	Glu	Asp		
		770				775					780						
tat	tcc	aaa	caa	gcc	ctc	tca	ctg	gtg	cgc	aag	gcc	ctg	cat	gaa	gga		2517
Tyr	Ser	Lys	Gln	Ala	Leu	Ser	Leu	Val	Arg	Lys	Ala	Leu	His	Glu	Gly		
					790					795					800		
gtc	gga	agc	gga	agc	ggg	agc	ccg	gac	ggg	gct	gtg	gtg	caa	ggg	ctt		2565
Val	Gly	Ser	Gly	Ser	Gly	Ser	Pro	Asp	Gly	Ala	Val	Val	Gln	Gly	Leu		
				805					810					815			
gtg	gaa	aaa	ttg	gag	aaa	acc	aag	tcc	ctg	gcc	cag	cag	ttg	aca	agg		2613
Val	Glu	Lys	Leu	Glu	Lys	Thr	Lys	Ser	Leu	Ala	Gln	Gln	Leu	Thr	Arg		
			820					825					830				
gag	gcc	act	caa	gcg	gaa	att	gaa	gca	gat	agg	tct	tat	cag	cac	agt		2661
Glu	Ala	Thr	Gln	Ala	Glu	Ile	Glu	Ala	Asp	Arg	Ser	Tyr	Gln	His	Ser		
		835					840					845					

ctc cgc ctc ctg gat tca gtg tct ccg ctt cag gga gtc agt gat cag Leu Arg Leu Leu Asp Ser Val Ser Pro Leu Gln Gly Val Ser Asp Gln 850 855 860	2709
tcc ttt cag gtg gaa gaa gca aag agg atc aaa caa aaa gcg gat tca Ser Phe Gln Val Glu Glu Ala Lys Arg Ile Lys Gln Lys Ala Asp Ser 865 870 875 880	2757
ctc tca agc ctg gta acc agg cat atg gat gag ttc aag cgt aca caa Leu Ser Ser Leu Val Thr Arg His Met Asp Glu Phe Lys Arg Thr Gln 885 890 895	2805
aag aat ctg gga aac tgg aaa gaa gaa gca cag cag ctc tta cag aat Lys Asn Leu Gly Asn Trp Lys Glu Glu Ala Gln Gln Leu Leu Gln Asn 900 905 910	2853
gga aaa agt ggg aga gag aaa tca gat cag ctg ctt tcc cgt gcc aat Gly Lys Ser Gly Arg Glu Lys Ser Asp Gln Leu Leu Ser Arg Ala Asn 915 920 925	2901
ctt gct aaa agc aga gca caa gaa gca ctg agt atg ggc aat gcc act Leu Ala Lys Ser Arg Ala Gln Glu Ala Leu Ser Met Gly Asn Ala Thr 930 935 940	2949
ttt tat gaa gtt gag agc atc ctt aaa aac ctc aga gag ttt gac ctg Phe Tyr Glu Val Glu Ser Ile Leu Lys Asn Leu Arg Glu Phe Asp Leu 945 950 955 960	2997
cag gtg gac aac aga aaa gca gaa gct gaa gaa gcc atg aag aga ctc Gln Val Asp Asn Arg Lys Ala Glu Ala Glu Glu Ala Met Lys Arg Leu 965 970 975	3045
tcc tac atc agc cag aag gtt tca gat gcc agt gac aag acc cag caa Ser Tyr Ile Ser Gln Lys Val Ser Asp Ala Ser Asp Lys Thr Gln Gln 980 985 990	3093
gca gaa aga gcc ctg ggg agc gct gct gct gat gca cag agg gca aag Ala Glu Arg Ala Leu Gly Ser Ala Ala Ala Asp Ala Gln Arg Ala Lys 995 1000 1005	3141
aat ggg gcc ggg gag gcc ctg gaa atc tcc agt gag att gaa cag Asn Gly Ala Gly Glu Ala Leu Glu Ile Ser Ser Glu Ile Glu Gln 1010 1015 1020	3186
gag att ggg agt ctg aac ttg gaa gcc aat gtg aca gca gat gga Glu Ile Gly Ser Leu Asn Leu Glu Ala Asn Val Thr Ala Asp Gly 1025 1030 1035	3231
gcc ttg gcc atg gaa aag gga ctg gcc tct ctg aag agt gag atg Ala Leu Ala Met Glu Lys Gly Leu Ala Ser Leu Lys Ser Glu Met 1040 1045 1050	3276
agg gaa gtg gaa gga gag ctg gaa agg aag gag ctg gag ttt gac Arg Glu Val Glu Gly Glu Leu Glu Arg Lys Glu Leu Glu Phe Asp 1055 1060 1065	3321
acg aat atg gat gca gta cag atg gtg att aca gaa gcc cag aag Thr Asn Met Asp Ala Val Gln Met Val Ile Thr Glu Ala Gln Lys 1070 1075 1080	3366
gtt gat acc aga gcc aag aac gct ggg gtt aca atc caa gac aca Val Asp Thr Arg Ala Lys Asn Ala Gly Val Thr Ile Gln Asp Thr 1085 1090 1095	3411

```

ctc aac aca tta gac ggc ctc ctg cat ctg atg ggt atg tga      3453
Leu Asn Thr Leu Asp Gly Leu Leu His Leu Met Gly Met
    1100                      1105                      1110

accacaacc cacaaccttc cagctccatg ctccagggct ttgctccaga aactcacta 3513
tacctagccc cagcaaaggg gagtctcagc tttccttaag gatatcagta aatgtgcttt 3573
gtttccaggc ccagataact ttccggcaggt tcccttacat ttactggacc ctgtttttacc 3633
gttgctaaga tgggtcactg aacacctatt gcacttgggg gtaaaggtct gtggggccaaa 3693
gaacaggtgt atataagcaa cttcacagaa cacgagacag cttgggaatc ctgctaaaga 3753
gtctggcctg gaccctgaga agccagtga cagttttaag cagaggaata acatcaccac 3813
tgtatatattc agaaagatca ctagggcagc cgagtggagg aaagcttgaa gaggggggta 3873
gagagaaggc aggttgagac tacttaagat attgttgaaa taattgaaga gagaaatgac 3933
aggagcctgc tctaaggcag tagaatggtg gctgggaaga tgtgaaggaa gattttccca 3993
gtctgtgaag tcaagaatca ctggccggcc ggggtgtggtg gctcacgcct gtaattctag 4053
cactttggga gactgaagcg ggtggatcac ccgaggtcag gagttgaaga ccagcctggc 4113
caacatggtg aaaccctgtc tctactaaaa gtacaaaaat tagctggatg atggtggtgg 4173
gcgcctgtaa ttccagctac tcaggagtct gaggcaggag aatcgcttga acccaggagg 4233
cgaggttaca gtgagccaag attgcaccac tgctcttcca gcctgggaac agagagactg 4293
cctaaaaaaaa aaaaaaaaaa aaa                                     4316

```

```

<210> 4
<211> 1111
<212> PRT
<213> Homo sapiens

```

```

<400> 4

```

```

Met Pro Ala Leu Trp Leu Gly Cys Cys Leu Cys Phe Ser Leu Leu Leu
1          5          10          15

```

```

Pro Ala Ala Arg Ala Thr Ser Arg Arg Glu Val Cys Asp Cys Asn Gly
          20          25          30

```

```

Lys Ser Arg Gln Cys Ile Phe Asp Arg Glu Leu His Arg Gln Thr Gly
          35          40          45

```

```

Asn Gly Phe Arg Cys Leu Asn Cys Asn Asp Asn Thr Asp Gly Ile His
          50          55          60

```

```

Cys Glu Lys Cys Lys Asn Gly Phe Tyr Arg His Arg Glu Arg Asp Arg
          65          70          75          80

```

18/25

Cys Leu Pro Cys Asn Cys Asn Ser Lys Gly Ser Leu Ser Ala Arg Cys  
                   85                  90                  95

Asp Asn Ser Gly Arg Cys Ser Cys Lys Pro Gly Val Thr Gly Ala Arg  
                   100                  105                  110

Cys Asp Arg Cys Leu Pro Gly Phe His Met Leu Thr Asp Ala Gly Cys  
                   115                  120                  125

Thr Gln Asp Gln Arg Leu Leu Asp Ser Lys Cys Asp Cys Asp Pro Ala  
                   130                  135                  140

Gly Ile Ala Gly Pro Cys Asp Ala Gly Arg Cys Val Cys Lys Pro Ala  
                   145                  150                  155                  160

Val Thr Gly Glu Arg Cys Asp Arg Cys Arg Ser Gly Tyr Tyr Asn Leu  
                   165                  170                  175

Asp Gly Gly Asn Pro Glu Gly Cys Thr Gln Cys Phe Cys Tyr Gly His  
                   180                  185                  190

Ser Ala Ser Cys Arg Ser Ser Ala Glu Tyr Ser Val His Lys Ile Thr  
                   195                  200                  205

Ser Thr Phe His Gln Asp Val Asp Gly Trp Lys Ala Val Gln Arg Asn  
                   210                  215                  220

Gly Ser Pro Ala Lys Leu Gln Trp Ser Gln Arg His Gln Asp Val Phe  
                   225                  230                  235                  240

Ser Ser Ala Gln Arg Leu Asp Pro Val Tyr Phe Val Ala Pro Ala Lys  
                   245                  250                  255

Phe Leu Gly Asn Gln Gln Val Ser Tyr Gly Gln Ser Leu Ser Phe Asp  
                   260                  265                  270

Tyr Arg Val Asp Arg Gly Gly Arg His Pro Ser Ala His Asp Val Ile  
                   275                  280                  285

Leu Glu Gly Ala Gly Leu Arg Ile Thr Ala Pro Leu Met Pro Leu Gly  
                   290                  295                  300

Lys Thr Leu Pro Cys Gly Leu Thr Lys Thr Tyr Thr Phe Arg Leu Asn  
                   305                  310                  315                  320

Glu His Pro Ser Asn Asn Trp Ser Pro Gln Leu Ser Tyr Phe Glu Tyr  
                   325                  330                  335

Arg Arg Leu Leu Arg Asn Leu Thr Ala Leu Arg Ile Arg Ala Thr Tyr  
 340 345 350

Gly Glu Tyr Ser Thr Gly Tyr Ile Asp Asn Val Thr Leu Ile Ser Ala  
 355 360 365

Arg Pro Val Ser Gly Ala Pro Ala Pro Trp Val Glu Gln Cys Ile Cys  
 370 375 380

Pro Val Gly Tyr Lys Gly Gln Phe Cys Gln Asp Cys Ala Ser Gly Tyr  
 385 390 395 400

Lys Arg Asp Ser Ala Arg Leu Gly Pro Phe Gly Thr Cys Ile Pro Cys  
 405 410 415

Asn Cys Gln Gly Gly Gly Ala Cys Asp Pro Asp Thr Gly Asp Cys Tyr  
 420 425 430

Ser Gly Asp Glu Asn Pro Asp Ile Glu Cys Ala Asp Cys Pro Ile Gly  
 435 440 445

Phe Tyr Asn Asp Pro His Asp Pro Arg Ser Cys Lys Pro Cys Pro Cys  
 450 455 460

His Asn Gly Phe Ser Cys Ser Val Ile Pro Glu Thr Glu Glu Val Val  
 465 470 475 480

Cys Asn Asn Cys Pro Pro Gly Val Thr Gly Ala Arg Cys Glu Leu Cys  
 485 490 495

Ala Asp Gly Tyr Phe Gly Asp Pro Phe Gly Glu His Gly Pro Val Arg  
 500 505 510

Pro Cys Gln Pro Cys Gln Cys Asn Ser Asn Val Asp Pro Ser Ala Ser  
 515 520 525

Gly Asn Cys Asp Arg Leu Thr Gly Arg Cys Leu Lys Cys Ile His Asn  
 530 535 540

Thr Ala Gly Ile Tyr Cys Asp Gln Cys Lys Ala Gly Tyr Phe Gly Asp  
 545 550 555 560

Pro Leu Ala Pro Asn Pro Ala Asp Lys Cys Arg Ala Cys Asn Cys Asn  
 565 570 575

Pro Met Gly Ser Glu Pro Val Gly Cys Arg Ser Asp Gly Thr Cys Val  
 580 585 590

Cys Lys Pro Gly Phe Gly Gly Pro Asn Cys Glu His Gly Ala Phe Ser  
 595 600 605

Cys Pro Ala Cys Tyr Asn Gln Val Lys Ile Gln Met Asp Gln Phe Met  
 610 615 620

Gln Gln Leu Gln Arg Met Glu Ala Leu Ile Ser Lys Ala Gln Gly Gly  
 625 630 635 640

Asp Gly Val Val Pro Asp Thr Glu Leu Glu Gly Arg Met Gln Gln Ala  
 645 650 655

Glu Gln Ala Leu Gln Asp Ile Leu Arg Asp Ala Gln Ile Ser Glu Gly  
 660 665 670

Ala Ser Arg Ser Leu Gly Leu Gln Leu Ala Lys Val Arg Ser Gln Glu  
 675 680 685

Asn Ser Tyr Gln Ser Arg Leu Asp Asp Leu Lys Met Thr Val Glu Arg  
 690 695 700

Val Arg Ala Leu Gly Ser Gln Tyr Gln Asn Arg Val Arg Asp Thr His  
 705 710 715 720

Arg Leu Ile Thr Gln Met Gln Leu Ser Leu Ala Glu Ser Glu Ala Ser  
 725 730 735

Leu Gly Asn Thr Asn Ile Pro Ala Ser Asp His Tyr Val Gly Pro Asn  
 740 745 750

Gly Phe Lys Ser Leu Ala Gln Glu Ala Thr Arg Leu Ala Glu Ser His  
 755 760 765

Val Glu Ser Ala Ser Asn Met Glu Gln Leu Thr Arg Glu Thr Glu Asp  
 770 775 780

Tyr Ser Lys Gln Ala Leu Ser Leu Val Arg Lys Ala Leu His Glu Gly  
 785 790 795 800

Val Gly Ser Gly Ser Gly Ser Pro Asp Gly Ala Val Val Gln Gly Leu  
 805 810 815

Val Glu Lys Leu Glu Lys Thr Lys Ser Leu Ala Gln Gln Leu Thr Arg  
 820 825 830

Glu Ala Thr Gln Ala Glu Ile Glu Ala Asp Arg Ser Tyr Gln His Ser

835 840 845

Leu Arg Leu Leu Asp Ser Val Ser Pro Leu Gln Gly Val Ser Asp Gln  
850 855 860

Ser Phe Gln Val Glu Glu Ala Lys Arg Ile Lys Gln Lys Ala Asp Ser  
865 870 875 880

Leu Ser Ser Leu Val Thr Arg His Met Asp Glu Phe Lys Arg Thr Gln  
885 890 895

Lys Asn Leu Gly Asn Trp Lys Glu Glu Ala Gln Gln Leu Leu Gln Asn  
900 905 910

Gly Lys Ser Gly Arg Glu Lys Ser Asp Gln Leu Leu Ser Arg Ala Asn  
915 920 925

Leu Ala Lys Ser Arg Ala Gln Glu Ala Leu Ser Met Gly Asn Ala Thr  
930 935 940

Phe Tyr Glu Val Glu Ser Ile Leu Lys Asn Leu Arg Glu Phe Asp Leu  
945 950 955 960

Gln Val Asp Asn Arg Lys Ala Glu Ala Glu Glu Ala Met Lys Arg Leu  
965 970 975

Ser Tyr Ile Ser Gln Lys Val Ser Asp Ala Ser Asp Lys Thr Gln Gln  
980 985 990

Ala Glu Arg Ala Leu Gly Ser Ala Ala Ala Asp Ala Gln Arg Ala Lys  
995 1000 1005

Asn Gly Ala Gly Glu Ala Leu Glu Ile Ser Ser Glu Ile Glu Gln  
1010 1015 1020

Glu Ile Gly Ser Leu Asn Leu Glu Ala Asn Val Thr Ala Asp Gly  
1025 1030 1035

Ala Leu Ala Met Glu Lys Gly Leu Ala Ser Leu Lys Ser Glu Met  
1040 1045 1050

Arg Glu Val Glu Gly Glu Leu Glu Arg Lys Glu Leu Glu Phe Asp  
1055 1060 1065

Thr Asn Met Asp Ala Val Gln Met Val Ile Thr Glu Ala Gln Lys  
1070 1075 1080



22/25

Val Asp Thr Arg Ala Lys Asn Ala Gly Val Thr Ile Gln Asp Thr  
 1085 1090 1095

Leu Asn Thr Leu Asp Gly Leu Leu His Leu Met Gly Met  
 1100 1105 1110

<210> 5  
 <211> 530  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Portion of Domain III of laminin gamma 2

<400> 5  
 aattctgccca ggattgtgct tctggctaca agagagattc agcgagactg gggccttttg 60  
 gcacctgtat tccttgtaac tgtcaagggg gaggggcctg tgatccagac acaggagatt 120  
 gttattcagg ggatgagaat cctgacattg agtgtgctga ctgcccaatt ggtttctaca 180  
 acgatccgca cgacccccgc agctgcaagc catgtccctg tcataacggg ttcagctgct 240  
 cagtgattcc ggagacggag gaggtggtgt gcaataactg ccctcccggg gtcaccggtg 300  
 cccgctgtga gctctgtgct gatggctact ttggggaccc ctttggtgaa catggcccag 360  
 tgaggccttg tcagccctgt caatgcaaca gcaatgtgga cccagtgcc tctgggaatt 420  
 gtgaccggct gacaggcagg tgtttgaagt gtatccacaa cacagccggc atctactgcg 480  
 accagtgcaa agcaggctac ttcgggggacc cattggctcc caaccagca 530

<210> 6  
 <211> 177  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Portion of Domain III of laminin gamma 2.

<400> 6

Gln Phe Cys Gln Asp Cys Ala Ser Gly Tyr Lys Arg Asp Ser Ala Arg  
 1 5 10 15

Leu Gly Pro Phe Gly Thr Cys Ile Pro Cys Asn Cys Gln Gly Gly Gly  
 20 25 30

Ala Cys Asp Pro Asp Thr Gly Asp Cys Tyr Ser Gly Asp Glu Asn Pro  
 35 40 45

Asp Ile Glu Cys Ala Asp Cys Pro Ile Gly Phe Tyr Asn Asp Pro His

50

55

60

Asp Pro Arg Ser Cys Lys Pro Cys Pro Cys His Asn Gly Phe Ser Cys  
 65 70 75 80

Ser Val Met Pro Glu Thr Glu Glu Val Val Cys Asn Asn Cys Pro Pro  
 85 90 95

Gly Val Thr Gly Ala Arg Cys Glu Leu Cys Ala Asp Gly Tyr Phe Gly  
 100 105 110

Asp Pro Phe Gly Glu His Gly Pro Val Arg Pro Cys Gln Pro Cys Gln  
 115 120 125

Cys Asn Asn Asn Val Asp Pro Ser Ala Ser Gly Asn Cys Asp Arg Leu  
 130 135 140

Thr Gly Arg Cys Leu Lys Cys Ile His Asn Thr Ala Gly Ile Tyr Cys  
 145 150 155 160

Asp Gln Cys Lys Ala Gly Tyr Phe Gly Asp Pro Leu Ala Pro Asn Pro  
 165 170 175

Ala

<210> 7  
 <211> 681  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc feature  
 <223> Complete domain III of laminin gamma 2

<400> 7  
 tgtatatgtc ctgttgggta caaggggcaa ttctgccagg attgtgcttc tggctacaag 60  
 agagattcag cgagactggg gccttttggc acctgtattc cttgtaactg tcaaggggga 120  
 ggggcctgtg atccagacac aggagattgt tattcagggg atgagaatcc tgacattgag 180  
 tgtgctgact gcccaattgg tttctacaac gatccgcacg acccccgag ctgcaagcca 240  
 tgtccctgtc ataacgggtt cagctgctca gtgattccgg agacggagga ggtggtgtgc 300  
 aataactgcc ctcccggggt caccggtgcc cgctgtgagc tctgtgctga tggctacttt 360  
 ggggaccctt ttggtgaaca tggcccagtg aggccttgtc agccctgtca atgcaacagc 420  
 aatgtggacc ccagtgcctc tgggaattgt gaccggctga caggcagggtg tttgaagtgt 480  
 atccacaaca cagccggcat ctactgagc cagtgcgaag caggctactt cggggacca 540

ttggctccca acccagcaga caagtgtcga gcttgcaact gtaaccccat gggctcagag 600  
 cctgtaggat gtcgaagtga tggcacctgt gtttgcaagc caggatttgg tggccccaac 660  
 tgtgagcatg gagcattcag c 681

<210> 8  
 <211> 227  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Complete domain III of laminin gamma 2.

<400> 8

Cys Ile Cys Pro Val Gly Tyr Lys Gly Gln Phe Cys Gln Asp Cys Ala  
 1 5 10 15

Ser Gly Tyr Lys Arg Asp Ser Ala Arg Leu Gly Pro Phe Gly Thr Cys  
 20 25 30

Ile Pro Cys Asn Cys Gln Gly Gly Gly Ala Cys Asp Pro Asp Thr Gly  
 35 40 45

Asp Cys Tyr Ser Gly Asp Glu Asn Pro Asp Ile Glu Cys Ala Asp Cys  
 50 55 60

Pro Ile Gly Phe Tyr Asn Asp Pro His Asp Pro Arg Ser Cys Lys Pro  
 65 70 75 80

Cys Pro Cys His Asn Gly Phe Ser Cys Ser Val Met Pro Glu Thr Glu  
 85 90 95

Glu Val Val Cys Asn Asn Cys Pro Pro Gly Val Thr Gly Ala Arg Cys  
 100 105 110

Glu Leu Cys Ala Asp Gly Tyr Phe Gly Asp Pro Phe Gly Glu His Gly  
 115 120 125

Pro Val Arg Pro Cys Gln Pro Cys Gln Cys Asn Asn Asn Val Asp Pro  
 130 135 140

Ser Ala Ser Gly Asn Cys Asp Arg Leu Thr Gly Arg Cys Leu Lys Cys  
 145 150 155 160

Ile His Asn Thr Ala Gly Ile Tyr Cys Asp Gln Cys Lys Ala Gly Tyr  
 165 170 175

Phe Gly Asp Pro Leu Ala Pro Asn Pro Ala Asp Lys Cys Arg Ala Cys  
180 185 190

Asn Cys Asn Pro Met Gly Ser Glu Pro Val Gly Cys Arg Ser Asp Gly  
195 200 205

Thr Cys Val Cys Lys Pro Gly Phe Gly Gly Pro Asn Cys Glu His Gly  
210 215 220

Ala Phe Ser  
225

<210> 9

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<221> misc\_feature

<223> N-terminal portion of domain III of laminin gamma 2.

<400> 9

Cys Ile Cys Pro Val Gly Tyr Lys Gly  
1 5

<210> 10

<211> 41

<212> PRT

<213> Homo sapiens

<220>

<221> misc\_feature

<223> C-terminal portion of domain III of laminin gamma 2.

<400> 10

Asp Lys Cys Arg Ala Cys Asn Cys Asn Pro Met Gly Ser Glu Pro Val  
1 5 10 15

Gly Cys Arg Ser Asp Gly Thr Cys Val Cys Lys Pro Gly Phe Gly Gly  
20 25 30

Pro Asn Cys Glu His Gly Ala Phe Ser  
35 40

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
13 May 2004 (13.05.2004)

PCT

(10) International Publication Number  
**WO 2004/039401 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 39/395**,  
C07K 16/18, G01N 33/574

(21) International Application Number:  
PCT/EP2003/012012

(22) International Filing Date: 29 October 2003 (29.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/422,009 29 October 2002 (29.10.2002) US

(71) Applicants and

(72) Inventors: SALO, Sirpa [FI/FI]; University of Oulu,  
Box 3000, FIN-90014 Oulu (FI). TRYGGVASON, Karl  
[SE/SE]; Dept. of Medical Biochemistry and Biophysics,  
Karolinska Institutet, S-171 77 Stockholm (SE).

(74) Agent: VOSSIUS, Volker; Geibelstrasse 6, 81679 Munich  
(DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
3 June 2004

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: USE OF ANTIBODIES TO THE GAMMA 2 CHAIN OF LALLMININ 5 TO INHIBIT TUMOR GROWTH AND METASTASIS

(57) Abstract: The present invention provides a methods and compositions for inhibiting tumor growth and/or metastasis involving the administering to a subject with a laminin 5-secreting tumor of an amount effective to inhibit tumor growth and/or metastasis of an antibody that binds to one or more epitopes of the laminin 5  $\gamma$ 2 chain.



WO 2004/039401 A3

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/12012

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K39/395 C07K16/18 G01N33/574

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07K G01N C12Q C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/052307 A1 (KALLUNKI PEKKA ET AL) 2 May 2002 (2002-05-02) see inter alia (0091) and (0106) ---	1-13
X	US 5 660 982 A (PYKE CHARLES ET AL) 26 August 1997 (1997-08-26) claims ---	1-13
X	WO 02 30465 A (DELEU LAURENT ; LAND HARTMUT (US); UNIV ROCHESTER (US)) 18 April 2002 (2002-04-18) the whole document --- -/--	1-13

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

10 March 2004

Date of mailing of the international search report

26 MAR 2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

MICAEL OWALD /EÖ

## INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/EP 03/12012

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHIHRO MATSUI ET AL: "Gamma2 Chain of Laminin-5 Is Recognized By Monoclonal Antibody GB3" J. INVEST DERMATOL, vol. 105, 1995, pages 648-652, XP002272939 the whole document ---	1-13
X	K. HELLMAN ET AL: "Cancer of the vagina: Laminin-5gamma2 chain expression and prognosis" INT J GYNECOL CANCER, vol. 10, 2000, pages 391-396, XP002272940 the whole document ---	1-13
P,X	WO 03 016907 A (KATAYAMA MASAHIKO ;SEKIGUCHI KIYOTOSHI (JP); SANZEN NORIKO (JP); E) 27 February 2003 (2003-02-27) the whole document -----	1-13

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/12012

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 2002052307	A1	02-05-2002	US 6143505 A	07-11-2000
			US 5660982 A	26-08-1997
			US 2003100529 A1	29-05-2003
			AT 182180 T	15-07-1999
			AU 699183 B2	26-11-1998
			AU 3745195 A	26-04-1996
			CA 2201865 A1	11-04-1996
			DE 69510810 D1	19-08-1999
			DE 69510810 T2	04-11-1999
			DK 784703 T3	29-11-1999
			WO 9610646 A1	11-04-1996
			EP 0784703 A1	23-07-1997
			ES 2133813 T3	16-09-1999
			GR 3031488 T3	31-01-2000
-----				
US 5660982	A	26-08-1997	AT 182180 T	15-07-1999
			AU 699183 B2	26-11-1998
			AU 3745195 A	26-04-1996
			CA 2201865 A1	11-04-1996
			DE 69510810 D1	19-08-1999
			DE 69510810 T2	04-11-1999
			DK 784703 T3	29-11-1999
			WO 9610646 A1	11-04-1996
			EP 0784703 A1	23-07-1997
			ES 2133813 T3	16-09-1999
			GR 3031488 T3	31-01-2000
			US 2003100529 A1	29-05-2003
			US 2002052307 A1	02-05-2002
			US 6143505 A	07-11-2000
-----				
WO 0230465	A	18-04-2002	AU 9684601 A	22-04-2002
			CA 2425779 A1	18-04-2002
			EP 1326892 A2	16-07-2003
			WO 0230465 A2	18-04-2002
			US 2003224993 A1	04-12-2003
-----				
WO 03016907	A	27-02-2003	WO 03016907 A1	27-02-2003
-----				